http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://xbrl.sec.gov/country/2024#UShttp://xbrl.sec.gov/country/2024#UShttp://fasb.org/us-gaap/2024#OperatingIncomeLosshttp://fasb.org/us-gaap/2024#OperatingIncomeLosshttp://www.ecolab.com/20251231#InterestExpenseNethttp://www.ecolab.com/20251231#InterestExpenseNethttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://www.ecolab.com/20251231#InterestExpenseNethttp://www.ecolab.com/20251231#InterestExpenseNethttp://www.ecolab.com/20251231#InterestExpenseNet0000031462--12-312025FYfalsehttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrentP20YP8YP17YP15Yhttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrentP34Y0http://xbrl.sec.gov/country/2024#UShttp://xbrl.sec.gov/stpr/2024#CA http://xbrl.sec.gov/stpr/2024#IL http://xbrl.sec.gov/stpr/2024#MN http://xbrl.sec.gov/stpr/2024#NJ http://xbrl.sec.gov/stpr/2024#NY http://xbrl.sec.gov/stpr/2024#WIhttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://www.ecolab.com/20251231#OperatingLeaseLiabilityNoncurrentExcludedFromLongTermDebthttp://fasb.org/us-gaap/2024#OperatingIncomeLoss0000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-01-012025-12-310000031462ecl:EuroNotesMemberus-gaap:NetInvestmentHedgingMember2025-01-012025-12-310000031462us-gaap:NetInvestmentHedgingMember2025-01-012025-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-12-310000031462ecl:EuroNotesMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-12-310000031462us-gaap:NetInvestmentHedgingMember2024-01-012024-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-12-310000031462ecl:EuroNotesMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-12-310000031462us-gaap:NetInvestmentHedgingMember2023-01-012023-12-310000031462us-gaap:AdditionalPaidInCapitalMember2025-01-012025-12-310000031462us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310000031462us-gaap:TreasuryStockCommonMember2025-01-012025-12-310000031462us-gaap:CommonStockMember2025-01-012025-12-310000031462us-gaap:TreasuryStockCommonMember2024-01-012024-12-310000031462us-gaap:CommonStockMember2024-01-012024-12-310000031462us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000031462us-gaap:CommonStockMember2023-01-012023-12-310000031462us-gaap:TreasuryStockCommonMember2025-12-310000031462us-gaap:RetainedEarningsMember2025-12-310000031462us-gaap:ParentMember2025-12-310000031462us-gaap:NoncontrollingInterestMember2025-12-310000031462us-gaap:AdditionalPaidInCapitalMember2025-12-310000031462us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310000031462us-gaap:TreasuryStockCommonMember2024-12-310000031462us-gaap:RetainedEarningsMember2024-12-310000031462us-gaap:ParentMember2024-12-310000031462us-gaap:NoncontrollingInterestMember2024-12-310000031462us-gaap:AdditionalPaidInCapitalMember2024-12-310000031462us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000031462us-gaap:TreasuryStockCommonMember2023-12-310000031462us-gaap:RetainedEarningsMember2023-12-310000031462us-gaap:ParentMember2023-12-310000031462us-gaap:NoncontrollingInterestMember2023-12-310000031462us-gaap:AdditionalPaidInCapitalMember2023-12-310000031462us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000031462us-gaap:TreasuryStockCommonMember2022-12-310000031462us-gaap:RetainedEarningsMember2022-12-310000031462us-gaap:ParentMember2022-12-310000031462us-gaap:NoncontrollingInterestMember2022-12-310000031462us-gaap:AdditionalPaidInCapitalMember2022-12-310000031462us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000031462us-gaap:EmployeeStockOptionMember2022-12-310000031462us-gaap:EmployeeStockOptionMember2024-12-310000031462us-gaap:EmployeeStockOptionMember2023-12-310000031462us-gaap:EmployeeStockOptionMember2025-12-310000031462us-gaap:EmployeeStockOptionMember2024-01-012024-12-310000031462us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000031462ecl:RestrictedStockAwardsMember2025-12-310000031462ecl:PBRSUAwardsMember2025-12-310000031462ecl:RestrictedStockAwardsMember2024-12-310000031462ecl:PBRSUAwardsMember2024-12-310000031462ecl:RestrictedStockAwardsMember2023-12-310000031462ecl:PBRSUAwardsMember2023-12-310000031462ecl:RestrictedStockAwardsMember2022-12-310000031462ecl:PBRSUAwardsMember2022-12-310000031462ecl:RestrictedStockAwardsMember2025-01-012025-12-310000031462ecl:RestrictedStockAwardsMember2024-01-012024-12-310000031462ecl:PBRSUAwardsMember2024-01-012024-12-310000031462ecl:RestrictedStockAwardsMember2023-01-012023-12-310000031462ecl:PBRSUAwardsMember2023-01-012023-12-310000031462srt:MinimumMemberecl:RestrictedStockAwardsMember2025-01-012025-12-310000031462srt:MaximumMemberecl:RestrictedStockAwardsMember2025-01-012025-12-310000031462us-gaap:EmployeeStockOptionMember2025-01-012025-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:CombinedRestructuringPlanMember2025-01-012025-12-310000031462us-gaap:ForeignPlanMember2025-01-012025-12-310000031462ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462srt:LatinAmericaMemberecl:WaterServicesMember2025-01-012025-12-310000031462srt:LatinAmericaMemberecl:GlobalPestEliminationMember2025-01-012025-12-310000031462srt:LatinAmericaMemberecl:GlobalInstitutionalMember2025-01-012025-12-310000031462srt:LatinAmericaMemberecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462srt:EuropeMemberecl:WaterServicesMember2025-01-012025-12-310000031462srt:EuropeMemberecl:GlobalPestEliminationMember2025-01-012025-12-310000031462srt:EuropeMemberecl:GlobalInstitutionalMember2025-01-012025-12-310000031462srt:EuropeMemberecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462srt:AsiaPacificMemberecl:WaterServicesMember2025-01-012025-12-310000031462srt:AsiaPacificMemberecl:GlobalPestEliminationMember2025-01-012025-12-310000031462srt:AsiaPacificMemberecl:GlobalInstitutionalMember2025-01-012025-12-310000031462srt:AsiaPacificMemberecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462ecl:ServiceAndLeaseMemberecl:WaterServicesMember2025-01-012025-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalPestEliminationMember2025-01-012025-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalInstitutionalMember2025-01-012025-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462ecl:ProductAndEquipmentMemberecl:WaterServicesMember2025-01-012025-12-310000031462ecl:ProductAndEquipmentMemberecl:GlobalInstitutionalMember2025-01-012025-12-310000031462ecl:ProductAndEquipmentMemberecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:WaterServicesMember2025-01-012025-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalPestEliminationMember2025-01-012025-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalInstitutionalMember2025-01-012025-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462country:USecl:WaterServicesMember2025-01-012025-12-310000031462country:USecl:GlobalPestEliminationMember2025-01-012025-12-310000031462country:USecl:GlobalInstitutionalMember2025-01-012025-12-310000031462country:USecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462country:CNecl:WaterServicesMember2025-01-012025-12-310000031462country:CNecl:GlobalPestEliminationMember2025-01-012025-12-310000031462country:CNecl:GlobalInstitutionalMember2025-01-012025-12-310000031462country:CNecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462country:CAecl:WaterServicesMember2025-01-012025-12-310000031462country:CAecl:GlobalPestEliminationMember2025-01-012025-12-310000031462country:CAecl:GlobalInstitutionalMember2025-01-012025-12-310000031462country:CAecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462srt:LatinAmericaMemberecl:WaterServicesMember2024-01-012024-12-310000031462srt:LatinAmericaMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462srt:LatinAmericaMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462srt:LatinAmericaMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462srt:EuropeMemberecl:WaterServicesMember2024-01-012024-12-310000031462srt:EuropeMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462srt:EuropeMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462srt:EuropeMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462srt:AsiaPacificMemberecl:WaterServicesMember2024-01-012024-12-310000031462srt:AsiaPacificMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462srt:AsiaPacificMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462srt:AsiaPacificMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ServiceAndLeaseMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ProductAndEquipmentMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ProductAndEquipmentMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ProductAndEquipmentMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462country:USecl:WaterServicesMember2024-01-012024-12-310000031462country:USecl:GlobalPestEliminationMember2024-01-012024-12-310000031462country:USecl:GlobalInstitutionalMember2024-01-012024-12-310000031462country:USecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462country:CNecl:WaterServicesMember2024-01-012024-12-310000031462country:CNecl:GlobalPestEliminationMember2024-01-012024-12-310000031462country:CNecl:GlobalInstitutionalMember2024-01-012024-12-310000031462country:CNecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462country:CAecl:WaterServicesMember2024-01-012024-12-310000031462country:CAecl:GlobalPestEliminationMember2024-01-012024-12-310000031462country:CAecl:GlobalInstitutionalMember2024-01-012024-12-310000031462country:CAecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462us-gaap:CorporateNonSegmentMemberecl:ProductAndEquipmentMember2023-01-012023-12-310000031462srt:LatinAmericaMemberus-gaap:CorporateMember2023-01-012023-12-310000031462srt:LatinAmericaMemberecl:WaterServicesMember2023-01-012023-12-310000031462srt:LatinAmericaMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462srt:LatinAmericaMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462srt:LatinAmericaMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462srt:EuropeMemberus-gaap:CorporateMember2023-01-012023-12-310000031462srt:EuropeMemberecl:WaterServicesMember2023-01-012023-12-310000031462srt:EuropeMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462srt:EuropeMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462srt:EuropeMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462srt:AsiaPacificMemberus-gaap:CorporateMember2023-01-012023-12-310000031462srt:AsiaPacificMemberecl:WaterServicesMember2023-01-012023-12-310000031462srt:AsiaPacificMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462srt:AsiaPacificMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462srt:AsiaPacificMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:ServiceAndLeaseMemberecl:WaterServicesMember2023-01-012023-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:ServiceAndLeaseMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:ProductAndEquipmentMemberecl:WaterServicesMember2023-01-012023-12-310000031462ecl:ProductAndEquipmentMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:ProductAndEquipmentMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:WaterServicesMember2023-01-012023-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:IndiaMiddleEastAndAfricaMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462country:USus-gaap:CorporateMember2023-01-012023-12-310000031462country:USecl:WaterServicesMember2023-01-012023-12-310000031462country:USecl:GlobalPestEliminationMember2023-01-012023-12-310000031462country:USecl:GlobalInstitutionalMember2023-01-012023-12-310000031462country:USecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462country:CNecl:WaterServicesMember2023-01-012023-12-310000031462country:CNecl:GlobalPestEliminationMember2023-01-012023-12-310000031462country:CNecl:GlobalInstitutionalMember2023-01-012023-12-310000031462country:CNecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462country:CAus-gaap:CorporateMember2023-01-012023-12-310000031462country:CAecl:WaterServicesMember2023-01-012023-12-310000031462country:CAecl:GlobalPestEliminationMember2023-01-012023-12-310000031462country:CAecl:GlobalInstitutionalMember2023-01-012023-12-310000031462country:CAecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462us-gaap:CorporateMember2023-01-012023-12-310000031462ecl:WaterServicesMember2023-01-012023-12-310000031462ecl:GlobalPestEliminationMember2023-01-012023-12-310000031462us-gaap:OtherRestructuringMemberecl:OneEcolabInitiativeProgramMember2025-12-310000031462us-gaap:EmployeeSeveranceMemberecl:OneEcolabInitiativeProgramMember2025-12-310000031462ecl:PriorYearPlansMember2025-12-310000031462us-gaap:OtherRestructuringMemberecl:OneEcolabInitiativeProgramMember2024-12-310000031462us-gaap:EmployeeSeveranceMemberecl:OneEcolabInitiativeProgramMember2024-12-310000031462us-gaap:EmployeeSeveranceMemberecl:CombinedRestructuringPlanMember2024-12-310000031462ecl:PriorYearPlansMember2024-12-310000031462ecl:OneEcolabInitiativeProgramMember2024-12-310000031462ecl:CombinedRestructuringPlanMember2024-12-310000031462us-gaap:CostOfSalesMemberecl:OneEcolabInitiativeProgramMember2025-01-012025-12-310000031462ecl:OtherNonrecurringIncomeExpenseMemberecl:CombinedRestructuringPlanMember2025-01-012025-12-310000031462us-gaap:CostOfSalesMemberecl:OneEcolabInitiativeProgramMember2024-01-012024-12-310000031462us-gaap:CostOfSalesMemberecl:CombinedRestructuringPlanMember2024-01-012024-12-310000031462ecl:OtherNonrecurringIncomeExpenseMemberecl:CombinedRestructuringPlanMember2024-01-012024-12-310000031462us-gaap:CostOfSalesMemberecl:CombinedRestructuringPlanMember2023-01-012023-12-310000031462ecl:OtherNonrecurringIncomeExpenseMemberecl:CombinedRestructuringPlanMember2023-01-012023-12-310000031462ecl:TenYear2015SeniorNotesMember2025-07-012025-07-3100000314622024-01-012024-01-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2025-01-012025-12-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberecl:AccumulatedDefinedBenefitPlansAdjustmentSettlementChargesMember2025-01-012025-12-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-01-012024-12-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberecl:AccumulatedDefinedBenefitPlansAdjustmentSettlementChargesMember2024-01-012024-12-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-01-012023-12-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberecl:AccumulatedDefinedBenefitPlansAdjustmentSettlementChargesMember2023-01-012023-12-310000031462srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2025-12-310000031462srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2025-12-310000031462srt:MinimumMemberecl:DispensingAndMonitoringEquipmentMember2025-12-310000031462srt:MinimumMemberecl:BuildingsAndLeaseHoldsMember2025-12-310000031462srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2025-12-310000031462srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2025-12-310000031462srt:MaximumMemberecl:DispensingAndMonitoringEquipmentMember2025-12-310000031462srt:MaximumMemberecl:BuildingsAndLeaseHoldsMember2025-12-310000031462us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2024-08-012024-08-010000031462ecl:UndesignatedPreferredStockMember2025-12-310000031462ecl:BarclayWaterManagementMember2024-11-012024-11-300000031462ecl:PriorYearPlansMember2025-01-012025-12-310000031462ecl:TenYear2015SeniorNotesMemberecl:EuroNotesMemberus-gaap:NetInvestmentHedgingMember2025-07-012025-07-310000031462ecl:ProductAndEquipmentAndServiceAndLeaseMemberus-gaap:CostOfSalesMember2025-01-012025-12-310000031462ecl:ProductAndEquipmentAndServiceAndLeaseMemberus-gaap:CostOfSalesMember2024-01-012024-12-310000031462ecl:ServiceAndLeaseMemberus-gaap:CostOfSalesMember2023-01-012023-12-310000031462ecl:ProductAndEquipmentAndServiceAndLeaseMemberus-gaap:CostOfSalesMember2023-01-012023-12-310000031462us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-12-310000031462us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000031462us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000031462us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-12-310000031462us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310000031462us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310000031462us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2025-01-012025-12-310000031462us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2025-01-012025-12-310000031462us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-01-012024-12-310000031462us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-01-012024-12-310000031462us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-01-012023-12-310000031462us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-01-012023-12-310000031462us-gaap:MaterialReconcilingItemsMember2025-01-012025-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:MaterialReconcilingItemsMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:MaterialReconcilingItemsMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:MaterialReconcilingItemsMemberus-gaap:ScenarioAdjustmentMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462us-gaap:MaterialReconcilingItemsMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:MaterialReconcilingItemsMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:MaterialReconcilingItemsMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:MaterialReconcilingItemsMemberus-gaap:ScenarioAdjustmentMember2023-01-012023-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-12-310000031462us-gaap:MaterialReconcilingItemsMember2023-01-012023-12-3100000314622025-07-012025-12-310000031462srt:LatinAmericaMember2025-12-310000031462srt:EuropeMember2025-12-310000031462ecl:MeaMember2025-12-310000031462ecl:AsiaPacificExcludingGreaterChinaMember2025-12-310000031462country:US2025-12-310000031462country:CN2025-12-310000031462country:CA2025-12-310000031462srt:LatinAmericaMember2024-12-310000031462srt:EuropeMember2024-12-310000031462ecl:MeaMember2024-12-310000031462ecl:AsiaPacificExcludingGreaterChinaMember2024-12-310000031462country:US2024-12-310000031462country:CN2024-12-310000031462country:CA2024-12-310000031462us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000031462ecl:NalcoHoldingCompanyMember2025-01-012025-12-310000031462srt:MinimumMemberecl:NalcoHoldingCompanyMember2022-06-010000031462srt:MaximumMemberecl:NalcoHoldingCompanyMember2022-06-010000031462ecl:ThreeYear2025SeniorNotesMember2025-08-310000031462us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310000031462us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-12-310000031462us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310000031462us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310000031462us-gaap:NotesPayableOtherPayablesMember2025-12-310000031462us-gaap:NotesPayableOtherPayablesMember2024-12-310000031462ecl:MultiCurrencyRevolvingCreditFacilityMember2025-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000031462us-gaap:TradeNamesMember2025-12-310000031462ecl:NalcoHoldingCompanyMemberus-gaap:TrademarksMember2025-06-300000031462us-gaap:TradeNamesMember2024-12-310000031462us-gaap:ForeignTaxJurisdictionOtherMember2025-01-012025-12-310000031462country:CN2025-01-012025-12-310000031462country:CH2025-01-012025-12-310000031462ecl:NalcoHoldingCompanyMemberus-gaap:TrademarksMember2025-01-012025-12-310000031462ecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:GlobalInstitutionalMember2025-01-012025-12-310000031462ecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462ecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:WaterServicesMember2025-01-012025-12-310000031462ecl:GlobalPestEliminationMember2025-01-012025-12-310000031462ecl:WaterServicesMember2024-01-012024-12-310000031462ecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:WaterServicesMember2025-12-310000031462ecl:GlobalPestEliminationMember2025-12-310000031462ecl:GlobalInstitutionalMember2025-12-310000031462ecl:GlobalHealthcareAndLifeSciencesMember2025-12-310000031462ecl:WaterServicesMember2024-12-310000031462ecl:GlobalPestEliminationMember2024-12-310000031462ecl:GlobalInstitutionalMember2024-12-310000031462ecl:GlobalHealthcareAndLifeSciencesMember2024-12-310000031462srt:ScenarioPreviouslyReportedMemberecl:WaterServicesMember2023-12-310000031462srt:ScenarioPreviouslyReportedMemberecl:GlobalPestEliminationMember2023-12-310000031462srt:ScenarioPreviouslyReportedMemberecl:GlobalInstitutionalMember2023-12-310000031462srt:ScenarioPreviouslyReportedMemberecl:GlobalHealthcareAndLifeSciencesMember2023-12-310000031462srt:ScenarioPreviouslyReportedMember2023-12-310000031462ecl:WaterServicesMember2023-12-310000031462ecl:GlobalPestEliminationMember2023-12-310000031462ecl:GlobalInstitutionalMember2023-12-310000031462ecl:GlobalHealthcareAndLifeSciencesMember2023-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000031462us-gaap:OtherIntangibleAssetsMember2025-12-310000031462us-gaap:OtherIntangibleAssetsMember2024-12-310000031462us-gaap:TrademarksMember2025-12-310000031462us-gaap:PatentsMember2025-12-310000031462us-gaap:CustomerRelationshipsMember2025-12-310000031462ecl:OtherTechnologyMember2025-12-310000031462us-gaap:TrademarksMember2024-12-310000031462us-gaap:PatentsMember2024-12-310000031462us-gaap:CustomerRelationshipsMember2024-12-310000031462ecl:OtherTechnologyMember2024-12-310000031462us-gaap:RetainedEarningsMember2025-01-012025-12-310000031462us-gaap:ParentMember2025-01-012025-12-310000031462us-gaap:RetainedEarningsMember2024-01-012024-12-310000031462us-gaap:ParentMember2024-01-012024-12-310000031462us-gaap:NoncontrollingInterestMember2024-01-012024-12-310000031462us-gaap:RetainedEarningsMember2023-01-012023-12-310000031462us-gaap:ParentMember2023-01-012023-12-310000031462us-gaap:NoncontrollingInterestMember2023-01-012023-12-310000031462us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2024-04-270000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:SubsequentEventMember2026-02-260000031462currency:EURus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-12-310000031462currency:CNYus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-12-310000031462currency:CADus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-12-310000031462currency:EURus-gaap:CrossCurrencyInterestRateContractMember2025-12-310000031462currency:CNYus-gaap:CrossCurrencyInterestRateContractMember2025-12-310000031462currency:CADus-gaap:CrossCurrencyInterestRateContractMember2025-12-310000031462us-gaap:InterestRateSwapMember2025-12-310000031462us-gaap:ForeignExchangeForwardMember2025-12-310000031462us-gaap:CrossCurrencyInterestRateContractMember2025-12-310000031462currency:EURus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2024-12-310000031462currency:EURecl:ExistingCrossCurrencyInterestRateContractReplacedMemberus-gaap:NetInvestmentHedgingMember2024-12-310000031462currency:CNYus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2024-12-310000031462ecl:SeniorEuroNotesMemberus-gaap:NetInvestmentHedgingMember2024-12-310000031462us-gaap:InterestRateSwapMember2024-12-310000031462us-gaap:ForeignExchangeForwardMember2024-12-310000031462us-gaap:CrossCurrencyInterestRateContractMember2024-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2025-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2024-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberecl:InterestExpenseNetMember2023-01-012023-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2025-01-012025-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-01-012025-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2024-01-012024-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2023-01-012023-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000031462us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2025-01-012025-12-310000031462us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-12-310000031462us-gaap:CostOfSalesMember2025-01-012025-12-310000031462ecl:InterestExpenseNetMember2025-01-012025-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-12-310000031462us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310000031462us-gaap:CostOfSalesMember2024-01-012024-12-310000031462ecl:InterestExpenseNetMember2024-01-012024-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-12-310000031462us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000031462us-gaap:CostOfSalesMember2023-01-012023-12-310000031462ecl:InterestExpenseNetMember2023-01-012023-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2025-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2025-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-12-310000031462us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2024-12-310000031462us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000031462us-gaap:RealEstateMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:RealEstateMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:PrivateEquityFundsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:DebtSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462ecl:DistressedDebtInvestmentMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:RealEstateMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:RealEstateMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:PrivateEquityFundsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:DebtSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462ecl:DistressedDebtInvestmentMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:FairValueInputsLevel3Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:FairValueInputsLevel3Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000031462country:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000031462country:USus-gaap:DefinedBenefitPostretirementHealthCoverageMember2023-12-310000031462us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000031462country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000031462country:USus-gaap:DefinedBenefitPostretirementHealthCoverageMember2023-01-012023-12-310000031462country:USus-gaap:DefinedBenefitPostretirementHealthCoverageMember2024-01-012024-12-310000031462country:USus-gaap:PensionPlansDefinedBenefitMember2025-01-012025-12-310000031462country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000031462us-gaap:ForeignCountryMember2025-12-310000031462us-gaap:StateAndLocalJurisdictionMember2025-12-310000031462us-gaap:DomesticCountryMember2025-12-310000031462ecl:TenYear2025SeniorNotesMember2025-08-012025-08-310000031462ecl:ThreeYear2025SeniorNotesMember2025-01-012025-12-310000031462ecl:ThirtyYear2021SeniorNotesMember2025-01-012025-12-310000031462ecl:ThirtyYear2020SeniorNotesMember2025-01-012025-12-310000031462ecl:ThirtyYear2017SeniorNotesMember2025-01-012025-12-310000031462ecl:ThirtyYear2016SeniorNotesMember2025-01-012025-12-310000031462ecl:ThirtyYear2011SeniorNotesMember2025-01-012025-12-310000031462ecl:ThirtyFouryear2021seniornotesMember2025-01-012025-12-310000031462ecl:TenYear2025SeniorNotesMember2025-01-012025-12-310000031462ecl:TenYear2020SeniorNotesMember2025-01-012025-12-310000031462ecl:TenYear2020SeniorNotesMaturing2031Member2025-01-012025-12-310000031462ecl:TenYear2017SeniorNotesMember2025-01-012025-12-310000031462ecl:TenYear2016SeniorNotesMember2025-01-012025-12-310000031462ecl:TenYear2015SeniorNotesMember2025-01-012025-12-310000031462ecl:SixYear2021SeniorNotesMember2025-01-012025-12-310000031462ecl:FiveYear2022SeniorNotesMember2025-01-012025-12-310000031462ecl:ElevenYear2021SeniorNotesMember2025-01-012025-12-310000031462srt:MinimumMember2025-12-310000031462srt:MaximumMember2025-12-310000031462us-gaap:SeniorNotesMember2025-12-310000031462ecl:TenYear2015SeniorNotesMember2025-12-310000031462ecl:TenYear2025SeniorNotesMember2025-08-310000031462us-gaap:ConstructionLoanPayableMember2025-06-300000031462ecl:ThreeYear2025SeniorNotesMember2025-06-300000031462ecl:ThreeYear2025SeniorNotesMember2025-12-310000031462ecl:ThirtyYear2021SeniorNotesMember2025-12-310000031462ecl:ThirtyYear2020SeniorNotesMember2025-12-310000031462ecl:ThirtyYear2017SeniorNotesMember2025-12-310000031462ecl:ThirtyYear2016SeniorNotesMember2025-12-310000031462ecl:ThirtyYear2011SeniorNotesMember2025-12-310000031462ecl:ThirtyFouryear2021seniornotesMember2025-12-310000031462ecl:TenYear2025SeniorNotesMember2025-12-310000031462ecl:TenYear2020SeniorNotesMember2025-12-310000031462ecl:TenYear2020SeniorNotesMaturing2031Member2025-12-310000031462ecl:TenYear2017SeniorNotesMember2025-12-310000031462ecl:TenYear2016SeniorNotesMember2025-12-310000031462ecl:SixYear2021SeniorNotesMember2025-12-310000031462ecl:OtherLongTermDebtMember2025-12-310000031462ecl:FiveYear2022SeniorNotesMember2025-12-310000031462ecl:ElevenYear2021SeniorNotesMember2025-12-310000031462ecl:ThirtyYear2021SeniorNotesMember2024-12-310000031462ecl:ThirtyYear2020SeniorNotesMember2024-12-310000031462ecl:ThirtyYear2017SeniorNotesMember2024-12-310000031462ecl:ThirtyYear2016SeniorNotesMember2024-12-310000031462ecl:ThirtyYear2011SeniorNotesMember2024-12-310000031462ecl:ThirtyFouryear2021seniornotesMember2024-12-310000031462ecl:TenYear2020SeniorNotesMember2024-12-310000031462ecl:TenYear2020SeniorNotesMaturing2031Member2024-12-310000031462ecl:TenYear2017SeniorNotesMember2024-12-310000031462ecl:TenYear2016SeniorNotesMember2024-12-310000031462ecl:TenYear2015SeniorNotesMember2024-12-310000031462ecl:SixYear2021SeniorNotesMember2024-12-310000031462ecl:OtherLongTermDebtMember2024-12-310000031462ecl:FiveYear2022SeniorNotesMember2024-12-310000031462ecl:ElevenYear2021SeniorNotesMember2024-12-310000031462us-gaap:OperatingSegmentsMemberus-gaap:CorporateMember2025-01-012025-12-310000031462us-gaap:OperatingSegmentsMemberecl:WaterServicesMember2025-01-012025-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalPestEliminationMember2025-01-012025-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalInstitutionalMember2025-01-012025-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalHealthcareAndLifeSciencesMember2025-01-012025-12-310000031462us-gaap:OperatingSegmentsMember2025-01-012025-12-310000031462ecl:ServiceAndLeaseMember2025-01-012025-12-310000031462ecl:ProductAndEquipmentMember2025-01-012025-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:WaterServicesMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:CorporateNonSegmentMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMember2024-01-012024-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:CorporateNonSegmentMemberus-gaap:ScenarioAdjustmentMember2024-01-012024-12-310000031462us-gaap:OperatingSegmentsMemberus-gaap:CorporateMember2024-01-012024-12-310000031462us-gaap:OperatingSegmentsMemberecl:WaterServicesMember2024-01-012024-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalPestEliminationMember2024-01-012024-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalInstitutionalMember2024-01-012024-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalHealthcareAndLifeSciencesMember2024-01-012024-12-310000031462us-gaap:OperatingSegmentsMember2024-01-012024-12-310000031462ecl:ServiceAndLeaseMember2024-01-012024-12-310000031462ecl:ProductAndEquipmentMember2024-01-012024-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberus-gaap:CorporateMember2023-01-012023-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:WaterServicesMember2023-01-012023-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberus-gaap:CorporateMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:WaterServicesMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:WaterServicesMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForSegmentChangesMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberus-gaap:CorporateMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:WaterServicesMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462ecl:ValuedAt2025FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-12-310000031462ecl:ValuedAt2024FixedCurrencyRatesMemberus-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-12-310000031462ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMemberus-gaap:OperatingSegmentsMemberus-gaap:ScenarioAdjustmentMember2023-01-012023-12-310000031462us-gaap:OperatingSegmentsMemberus-gaap:CorporateMember2023-01-012023-12-310000031462us-gaap:OperatingSegmentsMemberecl:WaterServicesMember2023-01-012023-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalPestEliminationMember2023-01-012023-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalInstitutionalMember2023-01-012023-12-310000031462us-gaap:OperatingSegmentsMemberecl:GlobalHealthcareAndLifeSciencesMember2023-01-012023-12-310000031462us-gaap:OperatingSegmentsMember2023-01-012023-12-310000031462ecl:ServiceAndLeaseMember2023-01-012023-12-310000031462ecl:ProductAndEquipmentMember2023-01-012023-12-310000031462ecl:WarewashingProductsMemberecl:SalesRevenueTotalMemberus-gaap:ProductConcentrationRiskMember2025-01-012025-12-310000031462ecl:WarewashingProductsMemberecl:SalesRevenueTotalMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-12-310000031462ecl:WarewashingProductsMemberecl:SalesRevenueTotalMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-12-310000031462us-gaap:CommonStockMember2025-12-310000031462us-gaap:CommonStockMember2024-12-310000031462us-gaap:CommonStockMember2023-12-310000031462us-gaap:CommonStockMember2022-12-310000031462us-gaap:CommonStockMember2025-12-310000031462us-gaap:CommonStockMember2024-12-310000031462us-gaap:CommonStockMember2023-12-310000031462ecl:USCommercialPaperProgramMember2024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2025-12-310000031462ecl:OvivoSElectronicsMemberus-gaap:TrademarksMember2025-12-160000031462ecl:OvivoSElectronicsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2025-12-160000031462ecl:OvivoSElectronicsMemberus-gaap:CustomerRelationshipsMember2025-12-160000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:TrademarksMember2024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:NoncompeteAgreementsMember2024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberecl:OtherTechnologyMember2024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:NoncompeteAgreementsMember2023-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2023-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberecl:OtherTechnologyMember2023-12-310000031462ecl:BarclayWaterManagementMember2025-12-310000031462ecl:BarclayWaterManagementMember2024-12-3100000314622022-12-310000031462ecl:OvivoSElectronicsMemberus-gaap:TrademarksMember2025-12-162025-12-160000031462ecl:OvivoSElectronicsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2025-12-162025-12-160000031462ecl:OvivoSElectronicsMemberus-gaap:CustomerRelationshipsMember2025-12-162025-12-160000031462ecl:OvivoSElectronicsMember2025-12-162025-12-160000031462ecl:OperatingLeasesRecordedInPropertyPlantAndEquipmentMember2025-12-310000031462ecl:OperatingLeasesRecordedInPropertyPlantAndEquipmentMember2024-12-310000031462us-gaap:CommonStockMember2022-11-300000031462us-gaap:CommonStockMember2025-01-012025-12-310000031462us-gaap:CommonStockMember2024-01-012024-12-310000031462us-gaap:CommonStockMember2023-01-012023-12-310000031462ecl:SpecificLegalReserveAndRelatedLegalChargesMember2025-01-012025-12-310000031462ecl:SpecificLegalReserveAndRelatedLegalChargesMember2024-01-012024-12-310000031462ecl:SpecificLegalReserveAndRelatedLegalChargesMember2023-01-012023-12-310000031462us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2024-01-012024-12-310000031462srt:MinimumMemberus-gaap:EmployeeStockOptionMember2025-01-012025-12-310000031462srt:MaximumMemberus-gaap:EmployeeStockOptionMember2025-01-012025-12-310000031462ecl:PBRSUAwardsMember2025-01-012025-12-310000031462srt:MinimumMemberecl:PBRSUAwardsMember2025-01-012025-12-310000031462srt:MaximumMemberecl:PBRSUAwardsMember2025-01-012025-12-310000031462us-gaap:FacilityClosingMemberecl:CombinedRestructuringPlanMember2022-01-012024-12-310000031462ecl:ImmaterialRestructuringPlanMember2024-04-012024-06-300000031462us-gaap:EmployeeSeveranceMemberecl:OneEcolabInitiativeProgramMember2024-01-012024-12-310000031462us-gaap:EmployeeSeveranceMemberecl:CombinedRestructuringPlanMember2024-01-012024-12-310000031462us-gaap:EmployeeSeveranceMemberecl:CombinedRestructuringPlanMember2023-01-012023-12-310000031462ecl:ImmaterialRestructuringPlanMember2023-01-012023-12-310000031462ecl:OneEcolabInitiativeProgramMember2025-12-310000031462ecl:OneEcolabInitiativeProgramMember2026-02-280000031462ecl:ImmaterialRestructuringPlanMember2024-06-300000031462us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2025-01-012025-12-310000031462ecl:OtherNonrecurringIncomeExpenseMemberecl:OneEcolabInitiativeProgramMember2025-01-012025-12-310000031462us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2024-01-012024-12-310000031462ecl:OtherNonrecurringIncomeExpenseMemberecl:OneEcolabInitiativeProgramMember2024-01-012024-12-310000031462us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2023-01-012023-12-310000031462ecl:PublicNotesMember2025-01-012025-12-310000031462ecl:EcolabSavingsPlanAndEmployeeStockOwnershipPlanMember2025-01-012025-12-310000031462srt:MinimumMemberecl:EcolabSavingsPlanAndEmployeeStockOwnershipPlanMember2025-01-012025-12-310000031462srt:MaximumMemberecl:EcolabSavingsPlanAndEmployeeStockOwnershipPlanMember2025-01-012025-12-310000031462us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-01-012025-12-310000031462us-gaap:ForeignCountryMemberus-gaap:LuxembourgInlandRevenueMember2025-12-3100000314622023-06-3000000314622023-04-012023-06-300000031462us-gaap:NoncontrollingInterestMember2025-01-012025-12-310000031462ecl:NalcoHoldingCompanyMember2022-06-0100000314622022-06-010000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2025-01-012025-12-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-01-012024-12-310000031462us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-01-012023-12-3100000314622025-04-012025-06-300000031462us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2025-01-012025-12-310000031462us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberecl:GlobalSurgicalSolutionsBusinessMember2024-08-010000031462ecl:EuroDebtMaturingOnJanuary1520254Memberus-gaap:NetInvestmentHedgingMember2024-01-310000031462ecl:TenYear2015SeniorNotesMemberus-gaap:NetInvestmentHedgingMember2025-06-300000031462ecl:TenYear2015SeniorNotesMemberus-gaap:NetInvestmentHedgingMember2025-04-300000031462ecl:EuroDebtMaturingOnJanuary1520254Memberus-gaap:NetInvestmentHedgingMember2023-11-300000031462us-gaap:RealEstateMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462us-gaap:PrivateEquityFundsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462us-gaap:FixedIncomeSecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462us-gaap:BondsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462ecl:SmallCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462ecl:LargeCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462ecl:InternationalEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462ecl:EmergingMarketsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462ecl:DistressedDebtInvestmentMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462country:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310000031462us-gaap:RealEstateMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462us-gaap:PrivateEquityFundsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462us-gaap:FixedIncomeSecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462us-gaap:BondsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462ecl:SmallCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462ecl:LargeCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462ecl:InternationalEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462ecl:EmergingMarketsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462ecl:DistressedDebtInvestmentMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462country:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000031462us-gaap:QualifiedPlanMember2025-12-310000031462us-gaap:NonqualifiedPlanMember2025-12-310000031462us-gaap:QualifiedPlanMember2024-12-310000031462us-gaap:NonqualifiedPlanMember2024-12-310000031462country:USus-gaap:DefinedBenefitPostretirementHealthCoverageMember2025-01-012025-12-310000031462country:US2025-01-012025-12-310000031462us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000031462us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:FixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:FixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:BondsMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:SmallCapEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:SmallCapEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:LargeCapEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:InsuranceContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462ecl:EmergingMarketsMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:USTreasuryAndGovernmentMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:FixedIncomeSecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:CorporateDebtSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:CashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462us-gaap:CashAndCashEquivalentsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:BondsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:SmallCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:LargeCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462ecl:InternationalEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462ecl:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462ecl:EmergingMarketsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462country:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2025-12-310000031462us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:FixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:FixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:BondsMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:SmallCapEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:SmallCapEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:LargeCapEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:InsuranceContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462ecl:EmergingMarketsMemberus-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:USTreasuryAndGovernmentMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:FixedIncomeSecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:FairValueInputsLevel2Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:FairValueInputsLevel1Membercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:CorporateDebtSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:CashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462us-gaap:CashAndCashEquivalentsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:BondsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:SmallCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:LargeCapEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:InternationalEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462ecl:InternationalEquitySecuritiesMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462ecl:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462ecl:EmergingMarketsMembercountry:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462country:USecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember2024-12-310000031462us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462country:USus-gaap:PensionPlansDefinedBenefitMember2025-12-310000031462country:USus-gaap:DefinedBenefitPostretirementHealthCoverageMember2025-12-310000031462us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462country:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000031462country:USus-gaap:DefinedBenefitPostretirementHealthCoverageMember2024-12-310000031462srt:MinimumMemberus-gaap:CorporateDebtSecuritiesMembercountry:US2025-01-012025-12-310000031462srt:MaximumMemberus-gaap:CorporateDebtSecuritiesMembercountry:US2025-01-012025-12-310000031462us-gaap:CommercialPaperMember2025-12-310000031462ecl:USCommercialPaperProgramMember2025-12-310000031462ecl:EuropeanCommercialPaperMember2025-12-310000031462us-gaap:OtherRestructuringMemberecl:OneEcolabInitiativeProgramMember2025-01-012025-12-310000031462us-gaap:EmployeeSeveranceMemberecl:OneEcolabInitiativeProgramMember2025-01-012025-12-310000031462ecl:OneEcolabInitiativeProgramMember2025-01-012025-12-310000031462us-gaap:OtherRestructuringMemberecl:OneEcolabInitiativeProgramMember2024-01-012024-12-310000031462ecl:OneEcolabInitiativeProgramMember2024-01-012024-12-310000031462us-gaap:OtherRestructuringMemberecl:CombinedRestructuringPlanMember2022-01-012024-12-310000031462us-gaap:EmployeeSeveranceMemberecl:CombinedRestructuringPlanMember2022-01-012024-12-310000031462ecl:CombinedRestructuringPlanMember2022-01-012024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2025-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-12-310000031462ecl:OvivoSElectronicsMember2025-12-160000031462ecl:OtherNonrecurringIncomeExpenseMember2025-01-012025-12-310000031462ecl:OtherNonrecurringIncomeExpenseMember2024-01-012024-12-310000031462ecl:OtherNonrecurringIncomeExpenseMember2023-01-012023-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2025-01-012025-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2024-01-012024-12-310000031462us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-12-3100000314622023-12-3100000314622024-01-012024-12-3100000314622023-01-012023-12-3100000314622025-12-3100000314622024-12-3100000314622025-10-012025-12-3100000314622025-06-3000000314622026-01-3000000314622025-01-012025-12-31iso4217:CADiso4217:CHFecl:countryxbrli:sharesiso4217:USDxbrli:pureiso4217:EURecl:itemecl:locationecl:segmentiso4217:USDxbrli:sharesiso4217:CNY

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K


☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the fiscal year ended December 31, 2025


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-9328

ECOLAB INC.

(Exact name of registrant as specified in its charter)



Delaware		41-0231510
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1 Ecolab Place, St. Paul, Minnesota 55102
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: 1-800-232-6522

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $1.00 par value	ECL	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ⌧ Yes ◻ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ◻ Yes ⌧ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ⌧ Yes ◻ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files. ⌧ Yes ◻ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☒		Accelerated filer ☐
Non-accelerated filer ☐		Smaller reporting company ☐
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ YES ☒ NO

Aggregate market value of voting and non-voting common equity held by non-affiliates of registrant on June 30, 2025, the last business day of the Registrant’s most recently completed second fiscal quarter: $67,088,288,734 (see Item 12, under Part III hereof), based on a closing price of registrant’s Common Stock of $269.44 per share.

The number of shares of registrant’s Common Stock, par value $1.00 per share, outstanding as of January 30, 2026: 281,969,448 shares.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Proxy Statement for the Annual Meeting of Stockholders to be held May 7, 2026, and to be filed within 120 days after the registrant’s fiscal year ended December 31, 2025 (hereinafter referred to as “Proxy Statement”), are incorporated by reference into Part III.

Table of Contents

ECOLAB INC.

FORM 10-K

For the Year Ended December 31, 2025

TABLE OF CONTENTS


		Beginning Page
PART I
	Item 1. Business.	3
	Item 1A. Risk Factors.	16
	Item 1B. Unresolved Staff Comments.	22
	Item 1C. Cybersecurity.	22
	Item 2. Properties.	24
	Item 3. Legal Proceedings.	24
	Item 4. Mine Safety Disclosures.	24

PART II
	Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.	25
	Item 6. [Reserved].	25
	Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	26
	Item 7A. Quantitative and Qualitative Disclosures about Market Risk.	47
	Item 8. Financial Statements and Supplementary Data.	47
	Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.	96
	Item 9A. Controls and Procedures.	96
	Item 9B. Other Information.	96
	Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.	96

PART III
	Item 10. Directors, Executive Officers and Corporate Governance.	97
	Item 11. Executive Compensation.	97
	Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.	97
	Item 13. Certain Relationships and Related Transactions, and Director Independence.	97
	Item 14. Principal Accounting Fees and Services.	97

PART IV
	Item 15. Exhibit and Financial Statement Schedules.	98
	Item 16. Form 10-K Summary.	104

Table of Contents

PART I

Except where the context otherwise requires, references in this Form 10-K to (i) “Ecolab,” “Company,” “we” and “our” are to Ecolab Inc. and its subsidiaries, collectively; (ii) “Nalco” are to Nalco Company LLC, a wholly-owned subsidiary of the Company; (iii) “Purolite” are to Purolite LLC, a wholly-owned subsidiary of the Company and its subsidiaries, collectively; and (iv) “Purolite transaction” are to the Company’s acquisition of the shares of the subsidiaries and certain other affiliated entities of Purolite Corporation and substantially all of the assets of Purolite Corporation; and (iv) “Ovivo Electronics” are to Ovivo Inc., a wholly owned subsidiary of the Company and its subsidiaries, collectively.

Item 1. Business.

General Development of Business.

Ecolab was incorporated as a Delaware corporation in 1924. Our fiscal year is the calendar year ending December 31. International subsidiaries are included in the consolidated financial statements on the basis of their U.S. GAAP (accounting principles generally accepted in the United States of America) November 30 fiscal year ends to facilitate the timely inclusion of such entities in our consolidated financial reporting.

Narrative Description of Business.

General

A trusted partner for millions of customers, we are a global leader in water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. For more than a century, we have advanced innovation by integrating science-based solutions, data-driven insights, AI-technology and world-class service. This unique combination enables us to partner with customers to define what best-in-class looks like and scale it across their operations, helping them achieve peak performance. Today, we have $16 billion in annual sales, 48,000 associates and customers in more than 170 countries and 40 industries. We help protect one-third of the world’s food production and a quarter of the power generated while delivering innovative solutions across food, healthcare, data centers, microelectronics, life sciences and hospitality. Our comprehensive approach protects what’s vital, aiming by 2030 to help protect 2 billion people from infections and enough drinking water for 1 billion people while enhancing business performance.

We pursue a “One Ecolab” enterprise selling strategy, built on the legacy of 'circle the customer – circle the globe', where we provide an array of innovative programs, products and services designed to meet the operational and sustainability needs of our customers throughout the world. Through this strategy and the breadth of our product and service mix, one customer may utilize the offerings of several of our operating segments. Important in our value proposition for customers is our ability to produce improved results while reducing their water and energy use. With that in mind, we focus on continually innovating to optimize both our own operations and the solutions we provide to customers, aligning with our corporate strategy to address some of the world’s most pressing and complex sustainability challenges, such as water scarcity and climate change. The work we do matters, and the way we do it matters to our employees, customers, investors and the communities in which we and our customers operate.

Sustainability is core to our business strategy. We deliver sustainable solutions that help companies around the world achieve their business goals while reducing environmental impacts. We partner with customers around the world to reduce water and energy use as well as greenhouse gas emissions through our high-efficiency solutions. By partnering with our customers to help them do more with less through the use of our innovative and differentiated solutions, we aim to help our customers conserve more than 300 billion gallons of water annually by 2030. In 2024, we helped our customers conserve more than 226 billion gallons of water and avoid more than 4.6 million metric tons of greenhouse gas emissions.

The following description of our business is based upon our reportable segments as reported in our consolidated financial statements for the year ended December 31, 2025, which are located in Item 8 of Part II of this Form 10-K. Operating segments that share similar economic characteristics and future prospects, including the nature of the products and production processes, end-use markets, channels of distribution and regulatory environment, have been aggregated into four reportable segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences.

Table of Contents

Global Water

This reportable segment consists of the Light & Heavy, Food & Beverage and Paper operating segments, which provide water treatment and process applications and cleaning and sanitizing solutions, primarily to large industrial customers within the manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the three operating segments which comprise our Global Water reportable segment follow below.

Light & Heavy

Light & Heavy serves customers across industrial and institutional markets. Within Light & Heavy, our markets include food and beverage, manufacturing and transportation, institutional clients, including commercial buildings, hospitals, universities and hotels, and global high technology serving customers, including data centers and microelectronics. We also serve the power, chemicals, primary metals and mining and petroleum refining and fuels industries.

Light & Heavy provides water treatment products and technology programs for cooling water, ultra-pure water, wastewater, boiler water and process water applications. In addition to these solutions, we offer specialty programs to the petroleum and fuels industry – refining process applications, fuels and feedstocks additives. Our cooling water treatment programs are designed to control challenges associated with cooling water systems — corrosion, scale and microbial fouling and contamination — in open recirculating, once-through and closed systems. Our wastewater products and programs focus on improving overall plant economics, addressing compliance issues, optimizing equipment efficiency and improving operator capabilities and effectiveness. We provide integrated chemical and digitally-based solutions, process improvements and mechanical component modifications to optimize boiler performance and control corrosion and scale build-up. Our programs assist in more effectively managing water use for plant processes by optimizing the performance of treatment chemicals and equipment in order to minimize costs and maximize returns on investment.

Our offerings include specialty products such as scale and corrosion inhibitors, antifoulants, pre-treatment solutions, liquid cooling solutions, membrane treatments, coagulants and flocculants, anti-foamers, hydrogen sulfide removal, cold flow improvers, lubricity inhibitors, crude desalting and reactive monomer inhibitors, as well as our 3D TRASAR^TM technologies, which combine chemistry, remote services and monitoring and control. We provide products and programs for water treatment and process applications aimed at combining environmental benefits with economic gains for our customers. Typically, water savings, energy savings and operating efficiency are among our primary sources of value creation for our customers, with product quality and production enhancement improvements also providing key differentiating features for many of our offerings. Our offerings are sold primarily by our corporate account and field sales employees. The majority of our Light & Heavy revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of products and programs for chemical applications within the industrial water treatment and petroleum refining industries.

Food & Beverage

Food & Beverage provides cleaning and sanitation products and water programs to facilitate the processing of products for human consumption. Food & Beverage provides detergents, cleaners, sanitizers, lubricants, water solutions and animal health products, as well as cleaning systems, digitally-based dispensers, monitors and chemical injectors for the application of chemical products, primarily to dairy plants, dairy, swine and poultry farms, breweries and soft-drink bottling plants, as well as meat, poultry and other food processors. Food & Beverage is also a leading developer and marketer of antimicrobial products used in direct contact with meat, poultry, seafood and produce during processing in order to reduce microbial contamination. Food & Beverage also designs, engineers and installs clean-in-place process control systems and facility cleaning systems for its customer base. Water savings, energy savings, and operating efficiency are among our sources of value creation for our customers. Products for use in processing facilities are sold primarily by our corporate account and field sales employees, while products for use on farms are sold through dealers and independent, third-party distributors. The majority of our Food & Beverage revenue is from product and equipment sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of cleaning and sanitizing products and water programs to the dairy plant, dairy, swine and poultry farm, food, meat and poultry, and beverage/brewery processing industries.

Table of Contents

Paper

Paper provides water and process applications for the pulp and paper industry, offering a comprehensive portfolio of programs that are used in all principal steps of the papermaking process and across all grades of paper, including graphic grades, board and packaging, and tissue and towel. While Paper provides its customers with similar types of products and programs for water treatment and wastewater treatment as those offered by Light & Heavy, Paper also offers two specialty programs that differentiate its offerings from Light & Heavy —pulp applications and paper applications. Our pulp applications maximize process efficiency and increase pulp cleanliness and brightness in bleaching operations, as well as predict and monitor scaling potential utilizing on-line monitoring to design effective treatment programs and avoid costly failures. Our paper applications focus on improving our customers’ operational efficiency, in part through water savings, energy savings and operating efficiency. Advanced digital sensing, monitoring and automation combine with innovative chemistries and detailed process knowledge to provide a broad range of customer solutions. Specialty products include flocculants, coagulants, dewatering aids and digester yield additives. Our offerings are sold primarily by our corporate account and field sales employees. The majority of our Paper revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of water treatment products and process aids to the pulp and paper industry.

Global Institutional & Specialty

This reportable segment consists of the Institutional and Specialty operating segments, which provide specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government, education and retail industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the two operating segments which comprise our Global Institutional & Specialty reportable segment follow below.

Institutional

Institutional provides specialized cleaners and sanitizers, infection prevention solutions, food safety products and equipment, and a range of other products and programs to hospitality and healthcare institutions. Institutional sells specialized cleaners and sanitizers for washing dishes, glassware, flatware, foodservice utensils and kitchen equipment (“warewashing”), plus specialized cleaners for various applications throughout foodservice operations, on-premise laundries (typically used by hotel and healthcare customers) and general housekeeping functions. Further, we provide infection prevention solutions to acute care hospitals and long-term care centers, which include hand hygiene, hard surface disinfection, digital monitoring systems and instrument cleaning. We also sell food safety products and equipment, water filters, dishwasher racks and related kitchen sundries to the foodservice, lodging, educational and healthcare industries. Institutional also provides pool and spa treatment programs for hospitality and other commercial customers, as well as a broad range of janitorial cleaning and floor care products and programs to customers in hospitality, healthcare and commercial facilities. Institutional develops various digital monitoring and chemical dispensing systems which are used by our customers to efficiently and safely dispense our cleaners and sanitizers, and through these products, systems and our on-site sales and service expertise, develop better results for our customers including water savings, energy savings and operating efficiency. In addition, Institutional markets a lease program comprised of energy-efficient dishwashing machines, detergents, rinse additives and sanitizers, including full machine maintenance.

Institutional sells its products and programs primarily through its direct field sales and corporate account sales personnel. Corporate account sales personnel establish relationships and negotiate contracts with larger multi-unit or “chain” customers. We also utilize independent, third-party foodservice, broad-line, healthcare and janitorial distributors to provide logistics to end customers that prefer to work through these distributors. Many of these distributors also participate in marketing our product and service offerings to the end customers. Through our field sales personnel, we generally provide the same customer support to end-use customers supplied by these distributors as we do to direct customers. The majority of our Institutional revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of warewashing and laundry products and programs and infection prevention solutions to the food service, hospitality, hospitals and long-term care markets.

Specialty

Specialty supplies cleaning and sanitizing products and related items primarily to regional, national and international quick service restaurant (“QSR”) chains and food retailers (i.e., supermarkets and grocery stores). Its products include specialty and general purpose hard surface cleaners, degreasers, sanitizers, polishes, hand care products and assorted cleaning tools and equipment which are primarily sold under the “Ecolab” and “Kay” brand names. QSR’s program also includes a lease program comprised of energy-efficient dishwashing machines, detergents, rinse additives and sanitizers, including full machine maintenance. Specialty’s cleaning and sanitation programs are customized to meet the needs of the market segments it serves and are designed to provide highly effective cleaning performance, promote food safety, reduce labor, water and energy costs and enhance user and guest safety. A number of dispensing options are available for products in the core product range. Specialty supports its product sales with training programs and technical support designed to meet the special needs of its customers. Through our EcoSure Brand Protection business, Specialty also provides customized on-site evaluations, training and quality assurance services to foodservice and hospitality operations.

Table of Contents

Both Specialty’s QSR business and its food retail business utilize their corporate account sales force which manages relationships with customers at the corporate and regional office levels (and, in the QSR market segment, at the franchisee level) and their field sales force which provides program support at the individual restaurant or store level. QSR customers are primarily supplied through third party distributors while most food retail customers utilize their own distribution networks. While Specialty’s customer base has broadened significantly over the years, Specialty’s business remains largely dependent upon a limited number of major QSR chains and franchisees and large food retail customers.

Food Safety Solutions supplies a digital platform that combines software, hardware and multiple services to automate kitchen procedures for efficiency and compliance. It also offers a unique variety of products, tools and equipment for food preparation, food rotation labeling, temperature management, cleaning and employee safety across all food service customers. The majority of our Specialty revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading suppliers of cleaning and sanitizing products to the global QSR market and the global food retail market.

Global Pest Elimination

This reportable segment consists of the Pest Elimination operating segment.

Pest Elimination

Pest Elimination provides services designed to detect, prevent and eliminate pests, such as rodents and insects, in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations and other commercial segments including education, life sciences and healthcare. The majority of our Pest Elimination revenue is from services and is recognized when the services are provided, which is over time.

In addition to the United States, which constitutes our largest operation, we operate in various regions, including in Asia Pacific, Greater China, Western Europe and Latin America.

We believe Pest Elimination is a leading service provider of effective, high-quality pest elimination programs that deliver high quality outcomes to commercial segments in the geographies it serves. As we expand the use of smart, connected devices, we believe our Pest Intelligence model will further contribute to our high-quality outcomes.

Global Life Sciences

This reportable segment consists of the Life Sciences operating segment.

Life Sciences

Life Sciences provides end-to-end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. These products are primarily sold under the “Ecolab” brand name, and include detergents, cleaners, sanitizers, disinfectants, surface wipes, as well as cleaning systems, electronic dispensers and chemical injectors for the application of chemical products. The Life Sciences portfolio includes premium fluid treatment and purification solutions with a broad range of unique products sold under the “Purolite” brand name, particularly focusing on biopharma purification solutions, active pharmaceutical ingredients (“APIs”) and high value industrial applications. The Life Sciences portfolio also includes decontamination systems and services utilizing hydrogen peroxide vapor, which are sold under the “Bioquell” brand name. The pharmaceutical clean room environment is the primary area that Ecolab and Bioquell products are utilized. Products and programs are sold primarily through our field sales and corporate account personnel, and to a lesser extent through distributors. The majority of our Life Sciences revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

Life Sciences is comprised of customers and accounts related to manufacturing in the following industries: pharmaceutical, animal health and medicine, blood purification and dialysis, biologic products, cosmetics and medical devices. Life Sciences also produces high performance purification resins that support critical separation processes across a range of industries, including power generation, food and beverage, and water treatment. Our tailored, comprehensive solutions and technical know-how focus on ensuring product quality, safety and compliance standards are met while improving operational efficiency in customers’ cleaning, sanitation and disinfection processes. We believe we are one of the leading suppliers of process purification solutions in Europe and North America and of contamination control solutions in Europe, with a growing presence in North America and other regions.

Table of Contents

Additional Information

International Operations

We directly operate in approximately 100 countries outside of the United States through wholly-owned subsidiaries or, in some cases, through a joint venture with a local partner. In certain countries, selected products are sold by our export operations to distributors, agents or licensees, although the volume of those sales is not significant in terms of our overall revenues. In general, our businesses conducted outside the United States are similar to those conducted in the United States.

Our business operations outside the United States are subject to the usual risks of foreign operations, including possible changes in trade and foreign investment laws, international business laws and regulations, tax laws, currency exchange rates and economic and political conditions. The profitability of our international operations is generally lower than the profitability of our businesses in the United States, due to (i) the additional cost of operating in numerous and diverse foreign jurisdictions with varying laws and regulations, (ii) higher costs of importing certain raw materials and finished goods in some regions, (iii) the smaller scale of international operations where certain operating locations are smaller in size and (iv) the additional reliance on distributors and agents in certain countries which can negatively impact our margins. Investments in sales and technical support are also necessary in certain geographies in order to facilitate the growth of our international operations.

Competition

In general, the markets in which the businesses in our Global Water reportable segment compete are led by a few large companies, with the rest of the market served by smaller entities focusing on more limited geographic regions or a smaller subset of products and services. Our businesses in this segment compete on the basis of their demonstrated value, technical expertise, innovation, digital technology, chemical formulations, global customer support, detection equipment, monitoring capabilities and dosing and metering equipment. Through the combination of our digitally enabled end-to-end water management and hygiene solutions, data-driven insights and personalized service, our Global Water businesses deliver outcomes that help our customers optimize water and energy use, improve productivity, advance food safety, and achieve sustainability and net zero goals, while optimizing total cost of operations.

The businesses in our Global Institutional & Specialty and Global Pest Elimination reportable segments have two significant classes of competitors. First, we compete with a small number of large companies selling directly or through distributors on a national or international scale. Second, we have numerous smaller regional or local competitors who focus on more limited geographies, product lines and/or end-use customer segments. We believe we compete principally by providing superior value, premium customer support, training, service, and innovative and differentiated products to help our customers protect their brand reputation and improve their operational efficiency.

Within the Global Life Sciences reportable segment, the business competes in the European market versus several mid-size and regional competitors and competes against two large and other mid-size or regional competitors in North America. Outside of North America and Europe competitors are much more fragmented and do not offer the same level of service or coverage as Ecolab. Our businesses in this segment compete by enabling our customers success through improved hygiene, digitally enabled programs in operating room and patient room space as well as a tailored approach to delivering key inputs that directly impact patients globally.

Sales

Our products, systems and services are primarily marketed in domestic and international markets by our Company-trained direct field sales personnel who also advise and assist our customers in the proper and most efficient use of the products and systems in order to meet a full range of cleaning and sanitation, water treatment and process chemistry needs. Independent, third-party distributors and, to a lesser extent, sales agents are utilized in several markets, as described in the segment descriptions found above. Currently the majority of our revenue is from product and sold equipment and is recognized at the point in time when the obligations in the contract with the customer are satisfied.

Customers and Classes of Products

We believe our business is not materially dependent upon a single customer. Additionally, although we have a diverse customer base and no customer or distributor constituted 10 percent or more of our consolidated revenues in 2025, 2024 or 2023, we do have customers and independent, third-party distributors, the loss of which could have a material adverse effect on results of operations for the affected earnings periods; however, we consider it unlikely that such an event would have a material adverse impact on our financial position. No material part of our business is subject to renegotiation or termination at the election of a governmental unit.

We sold one class of products within the Global Institutional & Specialty reportable segment which comprised 10% or more of consolidated net sales in the last three years. Sales of warewashing products were approximately 13% of consolidated net sales in 2025 and 12% in 2024 and 2023.

Table of Contents

Human Capital

As of December 31, 2025, Ecolab employed approximately 48,000 employees. The largest component of our workforce is comprised of more than 25,000 sales and service employees. Our innovation efforts are supported by approximately 3,000 research, development, engineering and digital experts. Approximately 43% of our employees are employed in North America, 21% in Europe, 12% in Latin America, 8% in Asia Pacific, 8% in India, Middle East and Africa, and 8% in Greater China.

We believe that doing the right thing, the right way, is good for business. We believe that by driving performance and growing fast, we can deliver a net positive impact in our own operations and what we deliver for our customers. We believe that Ecolab’s century-long growth, innovation and high performance have benefited from a workplace where individuals from all backgrounds are encouraged to reach their full potential. We believe in providing training and career development opportunities to all employees and in compensating and rewarding our employees equitably.

Our commitment to the safety of our employees, contractors, and customers is evident in the way we operate, the products we develop and the customers we serve. In addition, we are committed to promoting the health and well-being of our employees, our customers, and their customers by contributing to programs and initiatives that enhance the quality of life in the communities where they work and live. In support of these overall objectives, key areas of focus include:

Workplace Culture: Ecolab representatives engage daily with a diverse range of colleagues, customers and communities. We are committed to developing a culture where all voices are heard and equitable employment opportunities are available to everyone. To sustain our success, we work to embed our values of inclusivity and engagement throughout our people processes, including recruitment, retention and development.

We also have a vibrant and growing community of 12 Employee Resource Groups (“ERGs”) that are open to all Ecolab associates, to help employees connect with colleagues, take part in career and leadership development experiences, and provide important insights that help advance our workplace culture. All employees are welcome and encouraged to join, participate, or become leaders and allies within any of our ERGs.

Employee Training and Development: Ecolab’s growth has been characterized by a century of supporting customers by combining science, technology and innovation with the expertise of our associates. Beyond rigorous technical, functional, and business-specific training courses, our Global Corporate Flagship Development Programs for supervisors, managers and leaders are designed to deepen leadership capability and prepare potential successors for key leadership roles.

Compensation and Benefits: Ecolab has a market-competitive and performance-based pay philosophy, and we believe in compensating our employees fairly and equitably. We are committed to rewarding and recognizing employees for their contributions to the success of the organization. This includes our global merit increase program and our short- and long-term variable pay programs, which include goals and targets that are tied to the success of the business. We test our pay and wage data against compensation surveys to align our pay with the competitive external market. In the U.S., U.K., Ireland, and France, we conduct pay equity studies, and we are in the process of expanding our pay equity studies further to countries where we have a sizable presence.

Ecolab also provides market-competitive benefits based on country-specific needs and government requirements. While our benefits packages vary by market, they are designed to attract top talent and build long-term connections with our associates. Aligned to the applicable market and local regulations, elements of our benefits programs may include medical and dental insurance, retirement savings, employee stock purchase plan, paid time off, parental leave and adoption assistance, life and disability insurance, and employee assistance plans.

Safety, Health, and Wellness: At Ecolab, the safety of our employees and contractors is a priority and is embedded into our company values. Our safety goals are simple: zero accidents, zero injuries and zero violations. We communicate that this is a collective goal all employees commit to, own, and deliver on every day. Our leadership teams and a network of Safety, Health and Environment professionals around the world support employees with robust safety programs, processes and technologies. Understanding underlying and potential risks is a critical component to improving safety outcomes. Our Global Safety Dashboard tracks our performance on a range of leading and lagging safety indicators and helps us measure the effectiveness of our safety programs.

Additionally, a Be Well Program is available to U.S. employees and their families to empower, educate and support their personal journey to overall well-being by making positive lifestyle choices while creating a culture of wellness throughout Ecolab. Over the last year, we’ve expanded our physical, behavioral and financial well-being offerings with programs that leverage powerful technology and personalized coaching to support progress against wellness goals. Wellness initiatives outside the U.S. are aligned to country-specific needs and market practices; examples include employee assistance programs, caregiver support and programs focused on physical and mental health.

Table of Contents

Patents and Trademarks

We own and license a number of patents, trademarks and other intellectual property. While we have an active program to protect our intellectual property by filing for patents or trademarks and pursuing legal action, when appropriate, to prevent infringement, except for the items listed below, we do not believe our overall business is materially dependent on any individual patent or trademark.

●

Trademarks related to Ecolab, Nalco and 3D TRASAR, which collectively are material to all of our reportable segments. The Ecolab, Nalco and 3D TRASAR trademarks are registered or applied for in all of our key markets, and we anticipate maintaining them indefinitely.

Seasonality

We experience variability in our quarterly operating results due to seasonal sales volume and business mix fluctuations in our operating segments.

Investments in Equipment

We have invested, and plan to continue to invest, in process control and monitoring equipment and technology, consisting primarily of systems used by customers to dispense our products as well as to monitor water systems. The investment in such equipment is discussed under the heading "Investing Activities" in Part II, Item 7., “Management's Discussion and Analysis of Financial Condition and Results of Operations” (the “MD&A”), of this Form 10-K.

Manufacturing and Distribution

We manufacture most of our products and related equipment in Company-operated manufacturing facilities. Some products are also produced for us by third-party contract manufacturers. Other products and equipment are purchased from third-party suppliers. Additional information on product/equipment sourcing is found in the segment discussions above and additional information on our manufacturing facilities is located under Part I, Item 2., “Properties,” of this Form 10-K.

Deliveries to customers are made from our manufacturing plants and a network of distribution centers and third-party logistics service providers. We use common carriers, our own delivery vehicles, and distributors for transport. Additional information on our plant and distribution facilities is located under Part I, Item 2., “Properties,” of this Form 10-K.

Raw Materials

Raw materials purchased for use in manufacturing our products are inorganic chemicals, including alkalis, acids, biocides, phosphonates, phosphorous materials, silicates and salts; and organic chemicals, including acids, alcohols, amines, fatty acids, surfactants, solvents, monomers and polymers. Pesticides used by Pest Elimination are purchased as finished products under contract or purchase order from the producers or their distributors. We also purchase packaging materials for our manufactured products and components for our specialized cleaning equipment and systems. We purchase more than 10,000 raw materials, with the largest single raw material representing approximately five percent of raw material purchases. Our raw materials, with the exception of a few specialized chemicals which we manufacture, are generally purchased on an annual contract basis and are ordinarily available in adequate quantities from a diverse group of suppliers globally. When practical, global sourcing is used so that purchasing or production locations can be shifted to control product costs.

Research and Development

Our research and development program consists principally of developing and validating the performance of new products, processes, techniques and equipment, improving the efficiency of those already existing, improving service program content, evaluating the environmental compatibility of products and technical support. Key disciplines include analytical and formulation chemistry, microbiology, data science and predictive analytics, process and packaging engineering, digital and remote monitoring engineering and product dispensing technology. Substantially all of our principal products have been developed by our research, development and engineering personnel.

We believe continued research and development activities are critical to maintaining our leadership position within the industry and will provide us with a competitive advantage as we seek additional business with new and existing customers.

Joint Ventures

Over time, we have entered into partnerships or joint ventures in order to meet local ownership requirements, to achieve quicker operational scale, to expand our ability to provide our customers a more fully integrated offering or to provide other benefits to our business or customers. During 2025, the impact on our consolidated net income of our joint ventures, in the aggregate, was approximately two percent. We will continue to evaluate the potential for partnerships and joint ventures that can assist us in increasing our geographic, technological and product reach.

Table of Contents

Environmental and Regulatory Considerations

Our businesses are subject to various legislative enactments and regulations relating to the protection of the environment and public health. While we cooperate with governmental authorities and take commercially practicable measures to meet regulatory requirements and avoid or limit environmental effects, some risks are inherent in our businesses. Among the risks are costs associated with transporting and managing hazardous materials and waste disposal and plant site clean-up, fines and penalties if we are found to be in violation of law, as well as modifications, disruptions or discontinuation of certain operations or types of operations including product recalls and reformulations. Similarly, the need for certain of our products and services is dependent upon or might be limited by governmental laws and regulations. Changes in such laws and regulations, including among others, air, water, chemical and product regulations, could impact the sales of some of our products or services. In addition to an increase in costs of manufacturing and delivering products, a change in production regulations or product regulations could result in interruptions to our business and potentially cause economic or consequential losses should we be unable to meet the demands of our customers for products.

Additionally, although we are not currently aware of any such circumstances, there can be no assurance that future legislation or enforcement policies will not have a material adverse effect on our consolidated results of operations, financial position or cash flows. Environmental and regulatory matters most significant to us are discussed below.

Ingredient Legislation: Various laws and regulations have been enacted by state, local and foreign jurisdictions pertaining to the sale of products which contain phosphorous, volatile organic compounds, per- and polyfluoroalkyl substances or other ingredients that may impact human health or the environment. Under California Proposition 65, for example, label disclosures are required for certain products containing chemicals listed by California. Chemical management initiatives that promote pollution prevention through research and development of safer chemicals and safer chemical processes are being advanced by several states.

Environmentally preferable purchasing programs for cleaning products have been enacted in a number of states to date, and in recent years have been considered by several other state legislatures. Cleaning product ingredient disclosure legislation has been introduced in the U.S. Congress in each of the past few years but has not passed, and several states are considering further regulations in this area. In 2017, California passed the Cleaning Product Right to Know Act of 2017, that required ingredient transparency on-line and on-label by 2020 and 2021, respectively. The U.S. Government is monitoring “green chemistry” initiatives through a variety of initiatives, including its “Design for the Environment” (“DfE”)/“Safer Choice” program. DfE/Safer Choice has three broad areas of work (recognition of safer products on a DfE/Safer Choice label, development of best practices for industrial processes and evaluation of safer chemicals), and we are involved in these to varying degrees. Our Global Institutional and Global Water cleaning products are subject to the regulations and may incur additional stay-in-market expenses associated with conducting the required alternatives analyses for chemicals of concern. To date, we generally have been able to comply with such legislative requirements by reformulation or labeling modifications. Such legislation has not had a material adverse effect on our consolidated results of operations, financial position or cash flows to date.

TSCA: The nation’s primary chemicals management law, the Toxic Substances Control Act (“TSCA”), was updated with the passage of the Frank R. Lautenberg Chemical Safety for the 21st Century Act (“LCSA”) in 2016. The LCSA modernizes the original 1976 legislation, aiming to establish greater public confidence in the safety of chemical substances in commerce and improve the U.S. Environmental Protection Agency’s (“EPA”) capability and authority to regulate existing and new chemical substances. For Ecolab, the TSCA changes mainly impact testing and submission costs for new and existing chemical substances in the United States. As a result of reform and multiple administration changes, EPA reviews are resulting in the majority of new substances being regulated in some manner by the agency. As the agency continues to review existing chemistries, the likelihood that substances manufactured, imported, or processed by Ecolab may be subject to additional testing costs and/or risk management decisions is increasing. Future EPA risk evaluation decisions may result in the reduction or elimination of future uses for some products. Compliance with new requirements under TSCA are similar to the costs associated with REACH in the European Union, which is discussed below.

REACH: The European Union has enacted a regulatory framework for the Registration, Evaluation and Authorization of Chemicals (“REACH”), which aims to manage chemical safety risks. REACH established a European Chemicals Agency (“ECHA”) in Helsinki, Finland, which is responsible for evaluating data to determine hazards and risks and to manage this program for authorizing chemicals for sale and distribution in Europe. We met all REACH registration requirements. To help manage this program, we have been simplifying our product lines and working with chemical suppliers to comply with registration requirements. In addition, Korea, Taiwan, Ukraine, Turkey, India, Peru, Chile and Colombia and other countries have implemented or are implementing similar requirements. In addition, the European Commission has announced a revision of the REACH Regulation, with a legislative proposal expected in the third quarter of 2026, introducing simplified but stricter chemical controls that may increase compliance requirements and affect parts of Ecolab’s raw material portfolio; however, the potential financial impact is not yet fully quantifiable and is not expected to have a material adverse effect on our consolidated results of operations, cash flows, or financial position.

Table of Contents

GHS: In 2003, the United Nations adopted a standard on hazard communication and labeling of chemical products known as the Globally Harmonized System of Classification and Labeling of Chemicals (“GHS”). GHS is designed to facilitate international trade and increase safe handling and use of hazardous chemicals through a worldwide system that classifies chemicals based on their intrinsic hazards and communicates information about those hazards through standardized product labels and safety data sheets (“SDSs”). As of 2026, most countries in which we operate have adopted or are expected to adopt GHS-related legislation. The primary cost of compliance revolves around reclassifying products and revising SDSs and product labels. We have met applicable deadlines and are working toward a phased-in approach to mitigate the costs of GHS implementation in remaining countries (e.g., Ukraine, Chile, India). We are also implementing updates, where applicable, of GHS revisions in countries where it is already present (e.g., US, Canada). Potential costs to us are not expected to have a material adverse effect on our consolidated results of operations or cash flows in any one reporting period or on our financial position.

Pesticide and Biocide Legislation: Various international, federal and state environmental laws and regulations govern the manufacture and/or use of pesticides. We manufacture and sell certain disinfecting, sanitizing and material preservation products that kill or reduce microorganisms (bacteria, viruses, fungi) on hard environmental surfaces, in process fluids and on certain food products. Such products constitute “pesticides” or “antimicrobial pesticides” under the current definitions of the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), as amended by the Food Quality Protection Act of 1996, the principal federal statute governing the manufacture, labeling, handling and use of pesticides. We maintain several hundred product registrations with the U.S. Environmental Protection Agency (“EPA”). Registration entails the necessity to meet certain efficacy, toxicity and labeling requirements and to pay on-going registration fees. In addition, each state in which these products are sold requires registration and payment of a fee. In general, the states impose no substantive requirements different from those required by FIFRA. However, California and certain other states have adopted additional regulatory programs, and California imposes a tax on total pesticide sales in that state. While the cost of complying with rules as to pesticides has not had a material adverse effect on our consolidated results of operations, financial condition, or cash flows to date, the costs and delays in receiving necessary approvals for these products continue to increase. Total fees paid to the EPA and the states to obtain or maintain pesticide registrations are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position.

In Europe, the Biocidal Products Regulation established a program to evaluate and authorize marketing of biocidal active substances and products. We are working with suppliers and industry groups to manage these requirements and have met all relevant deadlines of the program by the timely submission of dossiers for active substances and biocide products. Anticipated registration costs, which will be incurred through the multi-year phase-in period, will be significant; however, these costs are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position. The same is true for emerging biocide regulations in Asia.

In addition, Pest Elimination applies restricted-use pesticides that it generally purchases from third parties. That business must comply with certain standards pertaining to the use of such pesticides and to the licensing of employees who apply such pesticides. Such regulations are enforced primarily by the states or local jurisdictions in conformity with federal regulations. We have not experienced material difficulties in complying with these requirements.

FDA Antimicrobial Product Requirements: Various laws and regulations have been enacted by federal, state, local and foreign jurisdictions regulating certain products manufactured and sold by us for controlling microbial growth on humans, animals and foods. In the United States, these requirements generally are administered by the U.S. Food and Drug Administration ("FDA"). However, the U.S. Department of Agriculture and EPA also may share in regulatory jurisdiction of antimicrobials applied to food. The FDA codifies regulations for these product categories in order to ensure product quality, safety and effectiveness. The FDA also has been expanding requirements applicable to such products, including proposing regulations for over-the-counter antiseptic drug products, which may impose additional requirements associated with antimicrobial hand care products and associated costs when finalized by the FDA.

Medical Device, Drug and Cosmetic Product Requirements: As a manufacturer, distributor and marketer of medical devices and human drugs, we also are subject to regulation by the FDA and corresponding regulatory agencies of the state, local and foreign governments in which we sell our products. These regulations govern the development, testing, manufacturing, packaging, labeling, distribution and marketing of medical devices and medicinal products, including APIs, excipients and resins for biopharmaceutical processing.

Table of Contents

●

In the United States, we are required to register with the FDA as a medical device, drug and cosmetic manufacturer, comply with post-market reporting (e.g., Adverse Event Reporting, MDR and Recall) requirements, and to comply with the FDA’s current Good Manufacturing Practices and Good Practice Guidelines (“GxPs”), which ensure that products are consistently produced and controlled according to quality standards and must be approved by the competent authorities.

●

Countries in the European Union require that certain products being sold within their jurisdictions obtain a “CE mark,” an international symbol of adherence to quality assurance standards, and be manufactured in compliance with certain requirements (e.g., Medical Device Regulation (EU) 2017/745 (“MDR”), and ISO 13485). We have CE mark approval to sell various medical devices. Implementation of the MDR has required additional investments, including system, product, process, technical file and product improvements. Additionally, pharmaceutical products in the EU must comply with regulations such as the GxP.

●

In Australia, products must comply with the regulations set by the Therapeutic Goods Administration. Medical devices must be included in the Australian Register of Therapeutic Goods and meet the Essential Principles for safety and performance. Therapeutic goods, including drugs and cosmetics, must adhere to specific standards and regulatory frameworks for safety, quality, efficacy, labelling, and claims.

●

Non-EU export markets are also subject to government regulation and country-specific rules and regulations.

Equipment: Ecolab’s products are dispensed by equipment that is subject to state and local regulatory requirements, as well as being subject to UL, NSF, and other approval requirements. For certain digitally connected product offerings, Federal Communication Commission and corresponding international requirements are applicable. We have both dedicated manufacturing facilities and third-party production of our equipment. We are developing processes to monitor and manage changing regulatory regimes and assist with equipment systems compliance. To date, such requirements have not had a material adverse effect on our consolidated results of operations, financial position or cash flows.

Other Environmental Legislation: Our manufacturing plants are subject to federal, state, local or foreign jurisdiction laws and regulations relating to discharge of hazardous substances into the environment and to the transportation, handling and disposal of such substances. The primary federal statutes that apply to our activities in the United States are the Clean Air Act, the Clean Water Act and the Resource Conservation and Recovery Act. We are also subject to the Superfund Amendments and Reauthorization Act of 1986, which imposes certain reporting requirements as to emissions of hazardous substances into the air, land and water. The products we produce and distribute into Europe are also subject to directives governing electrical waste (WEEE Directive 2012/19/EU) and restrictive substances (RoHS Directive 2011/65/EU). Similar legal requirements apply to Ecolab’s facilities globally. We make capital investments and expenditures to comply with environmental laws and regulations, to promote employee safety and to carry out our announced environmental sustainability principles. To date, such expenditures have not had a significant adverse effect on our consolidated results of operations, financial position or cash flows. Our capital expenditures for environmental, health and safety projects worldwide were approximately $62 million in 2025 and 2024, and $46 million in 2023. Approximately $59 million has been budgeted globally for projects in 2026.

Climate Change: Various laws and regulations addressing climate change are being implemented or considered at international, national, regional, and state levels, particularly focusing on reducing greenhouse gas (“GHG”) emissions. Notable regulations include California's 2023 GHG emissions reporting regulations addressing emissions, climate-related risks, and reduction claims, and the European Commission’s Corporate Sustainability Reporting Directive, which became effective January 2024 and is applicable to both EU and certain non-EU companies with a phased introduction. We are or may become subject to many of these laws. We continue to monitor and evaluate these regulations and incorporate reporting and disclosure obligations as appropriate.

Ecolab recognizes that climate change presents both risks and opportunities. We assess climate-related risks within our Enterprise Risk Management process, aligned with the Financial Stability Board’s Task Force on Climate-related Financial Disclosures (“TCFD”) recommendations. Our TCFD disclosures are available in our annual CDP Climate report on our website. Since our first TCFD-aligned climate risk assessment in 2021, we have continued to review and adapt our strategies to manage climate risks and leverage opportunities for customer impact. We also evaluate potential water-related risks in our operations, disclosing the results in our Growth and Impact Report. Future analyses will explore nature-related risks linked to climate and water, aligned with the Task Force on Nature-Related Financial Disclosures (“TNFD”) recommendations.

As a corporate policy, we support a balanced approach to reducing GHG emissions while sustaining economic growth. We have established climate related goals to further our commitment. In 2019, we announced goals to reduce operational GHG emissions by half by 2030 and achieve net zero by 2050, in alignment with the UN Global Compact’s Business Ambition for 1.5°C. In 2020, we further committed to move to 100% renewable energy by 2030 and set a science-based target (“SBT”) for Scope 1, 2, and 3 GHG emissions. In 2024, our net zero target for Science Based Targets initiative validation was approved, including a near term Scope 3 target. Our near-term SBT aims to reduce absolute Scope 1 and 2 emissions by 50% from 2018 levels, and Scope 3 emissions by 25% from 2022 levels, by 2030.

Table of Contents

In 2024, we invested $48 million and $4.3 million in capital and operating environmental program expenses, respectively. The investments resulted in a reduction of total energy consumption by almost 13.7 billion BTUs; reduction of emissions by 1,660.88 tCO2e; and over 48 million gallons (~184,000 cubic meters) of water savings from reduction and recycling projects. These reductions are calculated using direct measurements (such as meter readings and utility reports for water) and best-practice methodologies, with 2018 as the baseline year.

Beyond our operations, we help customers in over 170 countries reduce their energy and GHG emissions through high-efficiency solutions in cleaning, sanitation, water, paper, and energy services. Our 2030 goals include: customer GHG emissions reduction of 6.0 million metric tons; water stewardship to restore over 50% of our water withdrawal and achieve Alliance for Water Stewardship Standard certification in high-risk watersheds; and water conservation to reduce net water withdrawals by 40% per unit of production and help customers conserve over 300 billion gallons of water annually.

The science of sustainability is evolving. For factors that may affect our sustainability initiatives, goals, and targets, see Item 1A of Part I of this Form 10-K, entitled “Risk Factors.”

Environmental Remediation and Proceedings: Along with numerous other potentially responsible parties (“PRP”), we are currently involved with waste disposal site clean-up activities imposed by the federal Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”) or state equivalents at 16 sites in the United States. Additionally, we have similar liability at six sites outside the United States. In general, under CERCLA, we and each other PRP that actually contributed hazardous substances to a Superfund site are jointly and severally liable for the costs associated with cleaning up the site. Customarily, the PRPs will work with the EPA to agree and implement a plan for site remediation.

Based on an analysis of our experience with such environmental proceedings, our estimated share of all hazardous materials deposited on the sites referred to in the preceding paragraph, and our estimate of the contribution to be made by other PRPs which we believe have the financial ability to pay their shares, we have accrued our best estimate of our probable future costs relating to such known sites. In establishing accruals, potential insurance reimbursements are not included. The accrual is not discounted. It is not feasible to predict when the amounts accrued will be paid due to the uncertainties inherent in the environmental remediation and associated regulatory processes.

We have also been named as a defendant in a number of lawsuits alleging personal injury due to exposure to hazardous substances, including multi-party lawsuits alleging personal injury in connection with our products and services. While we do not believe that any of these suits will be material to us based upon present information, there can be no assurance that these environmental matters could not have, either individually or in the aggregate, a material adverse effect on our consolidated results of operations, financial position or cash flows.

We have also been named as a defendant in lawsuits where our products have not caused injuries, but the claimants wish to be monitored for potential future injuries. We cannot predict with certainty the outcome of any such tort claims or the involvement we or our products might have in such matters in the future, and there can be no assurance that the discovery of previously unknown conditions will not require significant expenditures. In each of these chemical exposure cases, our insurance carriers have accepted the claims on our behalf (with or without reservation) and our financial exposure should be limited to the amount of our deductible; however, we cannot predict the number of claims that we may have to defend in the future and we may not be able to continue to maintain such insurance.

Our worldwide net expenditures for contamination remediation were approximately $1.3 million in 2025, $0.7 million in 2024 and $0.3 million in 2023. Our worldwide accruals at December 31, 2025 for probable future remediation expenditures, excluding potential insurance reimbursements, totaled approximately $21.5 million. We review our exposure for contamination remediation costs periodically and our accruals are adjusted as considered appropriate. While the final resolution of these issues could result in costs below or above current accruals and, therefore, have an impact on our consolidated financial results in a future reporting period, we believe the ultimate resolution of these matters will not have a material effect on our consolidated results of operations, financial position or cash flows.

Available Information.

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC at https://www.sec.gov.

General information about us, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as any amendments and exhibits to those reports, are available free of charge through our website at https://investor.ecolab.com as soon as reasonably practicable after we file them with, or furnish them to, the SEC.

In addition, the following governance materials are available on our web site at https://investor.ecolab.com/governance/corporate-governance: (i) charters of the Audit, Compensation & Human Capital Management, Finance, Governance, and Safety, Health & Environment Committees of our Board of Directors; (ii) our Board's Corporate Governance Principles; and (iii) our Code of Conduct.

We include our website addresses throughout this report for reference only. The information contained on our websites, including the corporate responsibility, and climate reports identified in this report, is not incorporated by reference into this report.

Table of Contents

Information about our Executive Officers.

The persons listed in the following table are our current executive officers. Officers are elected annually and as needed by the Board of Directors. The Board of Directors routinely reviews the Company’s management structure and may make changes to the officers listed below at any time. There is no family relationship among any of the directors or executive officers and no executive officer has been involved during the past ten years in any legal proceedings described in applicable Securities and Exchange Commission regulations.


Name		Age		Office		Positions Held Since Jan. 1, 2021

Nicholas J. Alfano		64		Executive Vice President and President – Global Water		Apr. 2023 – Present
				Executive Vice President and General Manager – Global Light Sector		Jan. 2021 – Mar. 2023

Christophe Beck		58		Chairman and Chief Executive Officer		Oct. 2022 – Present
				Chairman, Chief Executive Officer and President		May 2022 – Oct. 2022
				President and Chief Executive Officer		Jan. 2021 – May 2022

Jandeen M. Boone		52		Executive Vice President, General Counsel and Secretary		Jan. 2025 – Present
				Executive Vice President, General Counsel, Secretary and Interim Chief Compliance Officer		June 2024 – Jan. 2025
				Senior Vice President, Chief Compliance Officer and Interim General Counsel		May 2024 – June 2024
				Interim General Counsel and Assistant Secretary		Apr. 2024 – May 2024
				Sector General Counsel, Institutional and International Markets		Feb. 2023 – Apr. 2024
				Sector General Counsel, Institutional and Specialty		Jan. 2022 – Jan. 2023
				Associate General Counsel, Institutional		Jan. 2021 – Dec. 2021

Jennifer J. Bradway		49		Senior Vice President and Corporate Controller		Jan. 2022 – Present
				Senior Vice President Finance - Global Institutional		Jan. 2021 – Dec. 2021

Darrell R. Brown		62		President and Chief Operating Officer		Oct. 2022 – Present
				Executive Vice President and President – Global Industrial		Jan. 2021 – Sept. 2022

Benjamin M. Clark (1)		45		Executive Vice President and Chief Supply Chain Officer		July 2025 – Present
				Senior Vice President Finance – Global Supply Chain		Aug. 2023 – July 2025

Gregory B. Cook		57		Executive Vice President and President – Institutional Group		Aug. 2023 – Present
				Executive Vice President and General Manager – Global Institutional		June 2021 – July 2023
				Senior Vice President and General Manager – Global Pest		Jan. 2021 – May 2021

Alexander A. De Boo		58		Executive Vice President and President – Global Markets		Feb. 2021 – Present
				Executive Vice President and President – Western Europe		Jan. 2021 – Feb. 2021

Alexandra M. A. Hlila		50		Executive Vice President and General Manager – Global Pest		Dec. 2024 – Present
				Senior Vice President – Strategy Institutional Group		Mar. 2024 – Dec. 2024
				Senior Vice President & General Manager – Institutional Europe		May 2022 – Feb. 2024
				Vice President Global & Corporate Accounts – Institutional Europe		May 2021 – Apr. 2022
				Vice President Field Sales Europe – Institutional Division		Jan. 2021 – Apr. 2021

Margeaux M. King (2)		49		Executive Vice President – Human Resources		Jan. 2025 – Present
				Senior Vice President, Global Total Rewards & Talent		Feb. 2022 – July 2022
				Senior Vice President Compensation & Benefits		Jan. 2021 – Jan. 2022

Scott D. Kirkland		52		Chief Financial Officer		Jan. 2022 – Present
				Senior Vice President and Corporate Controller		Jan. 2021 – Dec. 2021

Harpreet Saluja (3)		57		Executive Vice President – Corporate Strategy & Business Development		Nov. 2024 - Present

(1) Prior to joining Ecolab in August 2023, Mr. Clark was employed by Flagstone Foods, one of the largest manufacturers and distributors of private label healthy snacks in North America, as Chief Operating Officer and Chief Financial Officer from November 2021 until August 2023. Prior to Flagstone Foods, Mr. Clark was employed by GE Healthcare, a leading global medical technology and digital solutions innovator, as Chief Financial Officer of Global Services & Supply Chain from November 2020 until November 2021.

(2) Prior to re-joining Ecolab in 2025, Ms. King was employed by The Toro Company, a global maker of lawn, snow, and irrigation equipment, as Vice President, Human Resources from August 2022 until December 2024.

(3) Prior to joining Ecolab in November 2024, Ms. Saluja was employed by Eaton Corporation plc, a power management company, as Senior Vice President, Corporate Development and Planning from 2013 until 2024.

Table of Contents

Forward-Looking Statements

This Form 10-K, including Part I, Item 1, entitled “Business,” and the MD&A within Part II, Item 7, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include expectations concerning items such as:

●

amount, funding and timing of cash expenditures relating to our restructuring and other initiatives, as well as savings from such initiatives

●

future cash flows, access to capital, targeted credit rating metrics and impact of credit rating downgrade

●

adequacy of cash reserves

●

uses for cash, including dividends, share repurchases, debt repayments, capital investments and strategic business acquisitions

●

global economic and political environment

●

long-term potential of our business

●

impact of changes in exchange rates and interest rates, including the assessment and management of associated risks

●

customer retention rate

●

bad debt experience, non-performance of counterparties and losses due to concentration of credit risk

●

disputes, claims and litigation

●

environmental contingencies

●

impact and cost of complying with laws and regulations

●

sustainability and impact targets

●

returns on pension plan assets

●

contributions to pension and postretirement healthcare plans

●

amortization expense

●

impact of new accounting pronouncements

●

income taxes, including tax attributes, valuation allowances, unrecognized tax benefits, permanent reinvestment assertions and goodwill deductibility

●

recognition of share-based compensation expense

●

payments under operating leases

●

future benefit plan payments

●

market position

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will be,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof), “intends,” “could,” or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further discussion of these and other factors which could cause results to differ from those expressed in any forward-looking statement, see Item 1A of Part I of this Form 10-K, entitled “Risk Factors.” Except as may be required under applicable law, we undertake no duty to update our forward-looking statements.

Forward-looking and other statements in this document may also address our sustainability initiatives, goals, targets and progress, and the inclusion of such statements is not an indication that these contents are necessarily material to investors or required to be disclosed in our filings with the SEC. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future and performance against our goals and targets may differ from such forward-looking statements in such event.

Table of Contents

Item 1A. Risk Factors.

The following are important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-K. See the section entitled “Forward-Looking Statements” set forth above.

We may also refer to this disclosure to identify factors that may cause results to differ materially from those expressed in other forward-looking statements, including those made in oral presentations, such as telephone conferences and/or webcasts open to the public.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below in addition to the other information set forth in this Annual Report on Form 10-K, including "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operation" and our consolidated financial statements and the related notes, before making an investment decision. The risks described below are not the only risks or uncertainties we face. The occurrence of any of the following risks, additional risks and uncertainties not presently known to us, or risks that we currently believe to be immaterial, could materially and adversely affect our business, reputation, financial condition, prospects, or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your original investment. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below. The disclosures in this section reflect our beliefs and opinions as to factors that could materially and adversely affect us in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past.

Additionally, macroeconomic and geopolitical developments, including public health crises, escalating global conflicts, supply chain disruptions, labor market constraints, rising rates of inflation and high interest rates, may amplify many of the risks discussed below to which we are subject. The extent of the impact of macroeconomic and geopolitical developments on our financial and operating performance depends significantly on the duration and severity of such macroeconomic and geopolitical developments, the actions taken to contain or mitigate its impact and any changes in consumer behaviors as a result thereof.

Economic & Operational Risks

Our results are impacted by general worldwide economic factors.

Over the past year, changes in global trade policies, including the imposition of tariffs, import and export restrictions, and retaliatory trade actions, as well as implications of geopolitical situations in Europe, the Middle East, China, and Russia, have resulted in economic and demand uncertainty. Previously, the COVID pandemic, geopolitical instability and other global events have resulted in supply chain challenges, inflation, high interest rates, foreign currency exchange volatility, and volatility in global capital markets, which have affected our business and could have a material adverse impact on our business in the future. Countries such as Argentina and Turkey have experienced economic upheaval and similar upheaval in other countries with Ecolab operations could have a material adverse impact on our consolidated results of operations, financial position and cash flows by negatively impacting economic activity, including in our key end-markets, and by further weakening the local currency versus the U.S. dollar, resulting in reduced sales and earnings from our foreign operations, which are generated in the local currency, and then translated to U.S. dollars.

Our results depend upon the continued vitality of the markets we serve.

Economic downturns, and in particular downturns in our larger markets, including the foodservice, hospitality, travel, health care, food processing, refining, pulp and paper, mining and steel industries, can adversely impact our customers, and we may find it difficult to restore margins by maintaining pricing due to easing inflation from slowing economic growth. Recently, the war and energy crisis in Europe have resulted in a more challenging macroeconomic environment with significantly impacted costs and demand. Previously, the COVID-19 pandemic negatively impacted the demand for our products and services provided to customers in the full-service restaurant, hospitality, lodging and entertainment industries. In prior years, a weaker global economic environment has also negatively impacted certain of our other end-markets. During these periods of weaker economic activity, our customers and potential customers may reduce or discontinue their volume of purchases of cleaning and sanitizing products and water treatment and process chemicals, which has had, and may continue to have, a material adverse effect on our business, financial condition, results of operation or cash flows.

Our significant non-U.S. operations expose us to global economic, political and legal risks that could impact our profitability.

We have significant operations outside the United States, including joint ventures and other alliances. We conduct business in more than 170 countries and, in 2025, approximately 47% of our net sales were generated from customers outside the United States. There are inherent risks in our international operations, including:

●

exchange controls and currency restrictions;

●

currency fluctuations and devaluations;

●

changes in international trade policies, including the imposition of tariffs and other trade restrictions;

●

export duties and quotas;

●

changes in the availability and pricing of raw materials, energy and utilities;

●

changes in local economic conditions;

●

changes in laws and regulations, including the imposition of economic or trade sanctions affecting international commercial transactions;

Table of Contents

●

difficulties in managing international operations and the burden of complying with international and foreign laws;

●

requirements to include local ownership or management in our business;

●

economic and business objectives that differ from those of our joint venture partners;

●

exposure to possible expropriation, nationalization or other government actions;

●

restrictions on our ability to repatriate dividends from our subsidiaries;

●

unsettled political conditions, military action, civil unrest, acts of terrorism, force majeure, war or other armed conflict, including the Russian invasion of Ukraine, the Israel-Hamas conflict and other hostilities in the Middle East; and

●

countries whose governments have been hostile to U.S.-based businesses.

Following Russia’s invasion of Ukraine and the United States’ and other countries’ sanctions against Russia, we have limited our Russian business to operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses, and we may further narrow our presence in Russia depending on developments in the conflict or otherwise. While our operations in Russia and areas experiencing conflict are not material to our business and financial results, the escalation of these conflicts, or the imposition of additional sanctions by the United States, may also heighten many other risks disclosed in our report on Form 10-K, any of which could materially and adversely affect our business and financial results. Such risks include, but are not limited to, adverse effects on macroeconomic conditions, including increased inflation, constraints on the availability of commodities, supply chain disruption and decreased business spending; disruptions to our or our business partners’ global technology infrastructure, including through cyber-attack or cyber-intrusion; adverse changes in international trade policies and relations; claims, litigation and regulatory enforcement; our ability to implement and execute our business strategy; terrorist activities; our exposure to foreign currency fluctuations; reputational risk; and constraints, volatility, or disruption in the capital markets.

Additionally, changes in international trade policies by governments around the world, including the imposition or continuation of tariffs, could materially and adversely affect our business. During 2025, new tariffs were imposed in the U.S. for imports from a broad range of countries and materials. Several countries also implemented or proposed retaliatory tariffs on imports from the U.S., as well as other barriers to trade. Ongoing changes in U.S. trade policy through administrative action or litigation create a heightened level of uncertainty for our business. These tariffs, any new tariffs or policies imposed by governments around the world, or any resulting retaliatory measures, to the extent implemented, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.

Further, our operations outside the United States require us to comply with a number of United States and non-U.S. laws and regulations, including anti-corruption laws such as the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, as well as U.S. and non-U.S. economic sanctions regulations. We have internal policies and procedures relating to such laws and regulations; however, there is risk that such policies and procedures will not always protect us from the misconduct or reckless acts of employees or representatives, particularly in the case of recently acquired operations that may not have significant training in applicable compliance policies and procedures. Violations of such laws and regulations could result in disruptive investigations, significant fines and sanctions, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Also, because of uncertainties regarding the interpretation and application of laws and regulations and the enforceability of intellectual property and contract rights, we face risks in some countries that our intellectual property rights and contract rights would not be enforced by local governments. We are also periodically faced with the risk of economic uncertainty, which has impacted our business in some countries. Other risks in international business also include difficulties in staffing and managing local operations, including managing credit risk to local customers and distributors.

Our overall success as a global business depends, in part, upon our ability to succeed in differing economic, social, legal and political conditions. We may not continue to succeed in developing and implementing policies and strategies that are effective in each location where we do business, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Our increasing reliance on artificial intelligence (“AI”) technologies in our products, services, and operations presents several risks that could adversely impact our business, financial condition, and results of operations.

We are increasingly incorporating AI capabilities into the development of technologies and our business operations, and into our products and services. AI technology is complex and rapidly evolving and may subject us to significant competitive, legal, regulatory, operational and other risks, including the following:

●

Operational and Technical Risks: AI technologies are complex and rapidly evolving. Flaws in AI algorithms, training methodologies, or datasets may lead to unintended consequences, such as operational disruptions, erroneous decision-making, or data loss. These issues could impair the effectiveness of our AI systems and result in significant operational challenges. Additionally, software we purchase or lease from third-party vendors could become inoperable (via an attack from a bad actor, network failure, code error, etc.), such that it adversely impacts Ecolab’s ability to deliver products or services to its customers, resulting in financial losses, legal liabilities, and damage to our reputation.

●

Legal and Regulatory Risks: The legal and regulatory landscape for AI is still developing and varies across jurisdictions. Compliance with evolving AI regulations may impose significant costs, limit our ability to incorporate AI capabilities, and expose us to legal liabilities. Additionally, new regulations could conflict with our current AI practices, requiring costly changes to our development and deployment strategies.

Table of Contents

●

Reputational Risks: The use of AI raises social and ethical concerns, which could harm our reputation if not managed responsibly. Incidents related to AI, such as biased outcomes or privacy breaches, could lead to negative publicity and reduce public trust in our AI solutions.

●

Competitive Risks: Our competitors may develop and implement AI technologies more effectively, gaining a competitive advantage. If we fail to keep pace with advancements in AI, our market position could be weakened, adversely affecting our business performance.

●

Financial Risks: The development, testing, and deployment of AI systems are resource-intensive and may increase our operational costs. There is no assurance that our investments in AI will yield the anticipated benefits or that customers will adopt our AI-enhanced offerings, potentially impacting our financial results.

●

Cybersecurity Risks: AI systems can be vulnerable to cybersecurity threats, such as data breaches and unauthorized access. These threats could result in financial losses, legal liabilities, and damage to our reputation.

We are committed to developing and using AI responsibly, but there can be no guarantee that we will successfully mitigate all associated risks. Any failure in our AI initiatives could materially harm our business, financial condition, and results of operations.

We are subject to information technology system failures, network disruptions and breaches in data security.

We rely to a large extent upon information technology systems and infrastructure to operate our business. The size and complexity of our information technology systems and those of strategic vendors make them vulnerable to failure, malicious intrusion and random attack. Acquisitions have resulted in further de-centralization of systems and additional complexity in our systems infrastructure. Likewise, data security breaches by employees or others with permitted access to our systems or to the systems of strategic vendors pose a risk that sensitive data may be exposed to unauthorized persons or to the public. Geopolitical tensions or conflicts, such as Russia’s invasion of Ukraine, may further heighten the risk of cybersecurity attacks. While we have continually matured our security program and capabilities and have had no material incidents to date, cyber threats continue to evolve, such as with the use of artificial intelligence, resulting in sophisticated new attack methods that are increasingly automated, targeted, and difficult to defend against, and there can be no assurance that our efforts will prevent cybersecurity attacks or breaches in our systems or in the systems of strategic vendors, including cloud providers, that could cause reputational damage, business disruption or legal and regulatory costs; could result in third-party claims; could result in compromise or misappropriation of our intellectual property, trade secrets or sensitive information; or could otherwise materially adversely affect our business, including our business strategy, results of operations, or financial condition. Certain of our customer offerings include digital components, such as remote monitoring of certain customer operations. A breach of those remote monitoring systems could expose customer data giving rise to potential third-party claims and reputational damage. Additionally, it may take considerable time for us to investigate and evaluate the full impact of cyber-attacks, particularly for sophisticated attacks, which may inhibit our ability to provide prompt, full, and reliable information about cybersecurity incidents to our customers, regulators, and the public. There may also be other related challenges and risks as we complete implementation of our ERP system upgrade, and businesses which we have acquired, or may in the future acquire, may have information technology system vulnerabilities which could increase our risk of cybersecurity attacks. Although we maintain insurance, our insurance coverage may not be sufficient in type or amount to prevent or recover losses resulting from cybersecurity attacks.

Our results could be materially and adversely affected by difficulties in securing the supply of certain raw materials or by fluctuations in the cost of raw materials.

The prices of raw materials used in our business fluctuate, and in recent years we have experienced periods of significant increased raw material costs. Changes in raw material prices, unavailability of adequate and reasonably priced raw materials or substitutes for those raw materials, or the inability to obtain or renew supply agreements on favorable terms has materially and adversely affected our business and can in the future materially and adversely affect our consolidated results of operations, financial position or cash flows. In addition, volatility and disruption in economic activity and conditions could disrupt or delay the performance of our suppliers and thus impact our ability to obtain raw materials at favorable prices or on favorable terms, which may materially and adversely affect our business.

We may experience business disruption if we fail to execute organizational change and management transitions.

Our continued success will depend on the efforts and abilities of our executive officers and certain other key employees, particularly those with sales and sales management responsibilities, to drive business growth, development and profitability. Our operations could be materially and adversely affected if for any reason we are unable to successfully execute organizational change and management transitions at leadership levels.

Severe public health outbreaks not limited to COVID-19 may adversely impact our business.

The COVID-19 pandemic had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality and travel industries. Measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. Besides the COVID-19 pandemic, the United States and other countries have experienced, and may experience in the future, public health outbreaks such as Zika virus, Avian Flu, SARS and H1N1 influenza. A prolonged occurrence of a contagious disease such as these could result in a significant downturn in the foodservice, hospitality and travel industries and also may result in health or other government authorities imposing restrictions on travel further impacting our end markets. Any of these events could result in a significant drop in demand for some of our products and services and materially and adversely affect our business.

Table of Contents

Strategic Risks

If we are unsuccessful in integrating acquisitions our business could be materially and adversely affected.

We seek to acquire complementary businesses as part of our long-term strategy. There can be no assurance that we will find attractive acquisition candidates or succeed at effectively managing the integration of acquired businesses. If the underlying business performance of such acquired businesses deteriorates, the expected synergies from such transactions do not materialize or we fail to successfully integrate new businesses into our existing businesses, our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

If we are unsuccessful in executing on key business initiatives, our business could be materially and adversely affected.

We continue to execute key business initiatives as part of our ongoing efforts to improve our efficiency and returns. In particular, we are making supply chain investments to secure supply and add new capacity in our Life Sciences business. Additionally, we are continuing implementation of our ERP system upgrades, which are expected to continue in phases over the next several years. These upgrades, which include sales, supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades involve complex business process design and a failure of certain of these processes could result in business disruption. We are also undertaking restructuring programs including the One Ecolab initiative leveraging our digital technologies to realign the functional work done in many countries into global centers of excellence. This program is discussed along with other restructuring activities under Note 3, “Special (Gains) and Charges,” of the Notes of this Form 10-K. If the projects in which we are investing or the initiatives which we are pursuing are not successfully executed, our consolidated results of operations, financial position or cash flows could materially and adversely be affected.

Our growth depends upon our ability to compete successfully with respect to value, innovation and customer support.

We have numerous global, national, regional and local competitors. Our ability to compete depends in part on providing high quality and high value-added products, technology and service. We must also continue to identify, develop and commercialize innovative, profitable and high value-added products for niche applications and commercial digital applications. We have made significant investments in commercial digital product offerings, and our culture and expertise must continue to evolve to develop, support and profitably deploy commercial digital offerings, which are becoming an increasingly important part of our business. There can be no assurance that we will be able to accomplish our technology development goals or that technological developments by our competitors, including in the area of artificial intelligence, will not place certain of our products, technology or services at a competitive disadvantage in the future. In addition, certain of the new products that we have under development will be offered in markets in which we do not currently compete, and there can be no assurance that we will be able to compete successfully in those new markets. If we fail to introduce new technologies or commercialize our digital offerings on a timely and profitable basis, we may lose market share and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

Consolidation of our customers and vendors could materially and adversely affect our results.

Customers and vendors in the foodservice, hospitality, travel, healthcare, energy, life sciences, food processing and pulp and paper industries, as well as other industries we serve, have consolidated in recent years and that trend may continue. This consolidation could have a material adverse impact on our ability to retain customers and on our pricing, margins and consolidated results of operations.

We enter into multi-year contracts with customers that could impact our results.

Our multi-year contracts with some of our customers include terms affecting our pricing flexibility. There can be no assurance that these restraints will not have a material adverse impact on our margins and consolidated results of operations.

Legal, Regulatory & Compliance Risks

Our business depends on our ability to comply with laws and governmental regulations and meet our contractual commitments and failure to do so could materially and adversely impact our business; and we may be materially and adversely affected by changes in laws and regulations.

Our business is subject to numerous laws and regulations relating to the environment, including evolving climate change standards, and to the manufacture, storage, distribution, sale and use of our products as well as to the conduct of our business generally, including employment and labor laws and anti-corruption laws. Furthermore, increasing public and governmental awareness and concern regarding the effects of climate change has led to significant legislative and regulatory efforts to limit greenhouse gas emissions and will likely result in further environmental and climate change laws and regulations. Compliance with these laws and regulations exposes us to potential financial liability and increases our operating costs. A violation of these laws and regulations could expose us to financial liability that may have a material adverse effect on our results of operations and cash flows. Regulation of our products and operations continues to increase with more stringent standards, causing increased costs of operations and potential for liability if a violation occurs. The potential cost to us relating to environmental and product registration laws and regulations is uncertain due to factors such as the unknown magnitude and type of possible contamination and clean-up costs, the complexity and evolving nature of laws and regulations, and the timing and expense of compliance. Changes to current laws (including tax laws), regulations and policies could impose new restrictions, costs or prohibitions on our current practices which would have a material adverse effect on our consolidated results of operations, financial position or cash flows. Changes to labor and employment laws and regulations, as well as related rulings by courts and administrative bodies, could materially and adversely affect our operations and expose us to potential financial liability.

Defense of litigation, particularly certain types of actions such as antitrust, patent infringement, personal injury, product liability, breach of contract, wage hour and class action lawsuits, can be costly and time consuming even if ultimately successful, and if not successful could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Table of Contents

Our operations may present a safety risk to our employees and others.

Notwithstanding our emphasis on safety and the precautions we take related to health and safety, we may be unable to avoid safety incidents relating to our operations that result in injuries or deaths of our employees, contractors or others. Certain safety incidents may result in legal or regulatory action that could result in increased expenses or reputational damage. We maintain workers' compensation and other insurances to address the risk of incurring material liabilities for injuries or deaths, but there can be no assurance that the insurance coverage will be adequate or will continue to be available on terms acceptable to us, or at all, which could result in material liabilities to us for any injuries or deaths. Changes to federal, state, and local employee health and safety regulations, and legislative, regulatory, or societal responses to safety incidents may result in heightened regulations or public scrutiny that may increase our compliance costs or result in reputational damage.

A chemical spill or release could materially and adversely impact our business.

As a manufacturer and supplier of chemical products, there is a potential for chemicals to be accidentally spilled, released or discharged, either in liquid or gaseous form, during production, transportation, storage or use. Such a release could result in environmental contamination as well as a human or animal health hazard. Accordingly, such a release could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Potential indemnification liabilities pursuant to the separation and split-off of our Upstream Energy business could materially and adversely affect our business and financial statements.

With respect to the separation and subsequent split-off of our Upstream Energy business, we entered into a separation and distribution agreement with ChampionX Holding Inc. and ChampionX Corporation (f/k/a Apergy Corporation and taken together with ChampionX Holding Inc., “ChampionX”) as well as certain other agreements to govern the separation and related transactions and our relationship with ChampionX going forward. These agreements provide for specific indemnity and certain other obligations of each party and could lead to disputes between ChampionX and us. If we are required to indemnify ChampionX under the circumstances set forth in these agreements, we may be subject to substantial related liabilities. In addition, with respect to the liabilities for which ChampionX has agreed to indemnify us under these agreements, there can be no assurance that the indemnity rights we have against ChampionX will be sufficient to protect us against the full amount of such liabilities, or that ChampionX will be able to fully satisfy its indemnification obligations. Each of these risks could negatively affect our business and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

Extraordinary events may significantly impact our business.

The occurrence of (a) litigation or claims, (b) the loss or insolvency of a major customer or distributor, (c) repeated or prolonged federal government shutdowns or similar events, (d) war (including acts of terrorism or hostilities which impact our markets), (e) natural or manmade disasters, (f) water shortages or (g) severe weather conditions affecting our operations or the energy, foodservice, hospitality and travel industries may have a material adverse effect on our business.

While we have a diverse customer base and no customer or distributor constitutes 10 percent or more of our consolidated revenues, we do have customers and independent, third-party distributors, the loss of which could have a material adverse effect on our consolidated results of operations or cash flows for the affected earnings periods.

Government shutdowns can have a material adverse effect on our consolidated results of operations or cash flows by disrupting or delaying new product launches, renewals of registrations for existing products and receipt of import or export licenses for raw materials or products.

War (including acts of terrorism or hostilities), natural or manmade disasters, water shortages or severe weather conditions, including the effects of climate change, affecting the energy, foodservice, hospitality, travel, health care, food processing, pulp and paper, mining, steel and other industries can cause a downturn in the business of our customers, which in turn can have a material adverse effect on our consolidated results of operations, financial position or cash flows. In particular, the U.S. Gulf Coast is a region with significant refining, petrochemicals and chemicals operations which provide us raw materials, as well as being an important customer base for our Light & Heavy operating segment. Hurricanes or other severe weather events impacting the Gulf Coast, such as the winter freeze in Texas and the Gulf Coast in February 2021, can materially and adversely affect our ability to obtain raw materials at reasonable cost, or at all, and could adversely affect our business with our customers in the region.

Our commitments, goals, targets, objectives and initiatives related to sustainability, and our public statements and disclosures regarding them, expose us to numerous risks.

We have developed, and will continue to establish, goals, targets, and other objectives related to sustainability matters, including our sustainability goals in alignment with the United Nations Global Compact’s Business Ambition for 1.5⁰C and our commitments to science-based targets addressing Scope 1, 2 and 3 GHG emissions, discussed in Item 1 of Part I of this Form 10-K, entitled “Business.” Achieving these goals and commitments will require evolving our business, capital investment and the development of technology that might not currently exist. We might incur additional expense or be required to recognize impairment charges in connection with our efforts. These commitments, goals, targets and other objectives reflect our current plans and there is no guarantee that they will be achieved. Our efforts to research, establish, accomplish, and accurately report on these commitments, goals, targets, and objectives expose us to operational, reputational, financial, legal, and other risks. Our ability to achieve any stated commitment, goal, target, or objective is subject to factors and conditions, many of which are outside of our control, including the pace of changes in technology, the availability of requisite financing, and the availability of suppliers that can meet our sustainability and other standards.

Table of Contents

Our business may face increased scrutiny from the investment community, other stakeholders, regulators, and the media related to our sustainability activities, including our commitments, goals, targets, and objectives, and our methodologies and timelines for pursuing them. If our sustainability practices do not meet the rapidly evolving, varied and often times conflicting investor or other stakeholder expectations and standards, our reputation, our ability to attract or retain employees, and our attractiveness as an investment, business partner, or as an acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our commitments, goals, targets, and objectives, to comply with ethical, environmental, or other standards, regulations, or expectations, or to satisfy reporting standards with respect to these matters, within the timelines we announce, or at all, could have operational, reputational, financial and legal impacts.

Financial Risks

If the separation and split-off of our Upstream Energy business or certain internal transactions undertaken in anticipation of the divestiture are determined to be taxable in whole or in part, we and our stockholders may incur significant tax liabilities.

In connection with the separation and split-off of our Upstream Energy business that was consummated on June 3, 2020, we obtained opinions of outside tax counsel that the related merger and exchange offer will qualify as tax-free transactions to us and our stockholders, except to the extent that cash was paid to Ecolab stockholders in lieu of fractional shares. We have not sought or obtained a ruling from the Internal Revenue Service (“IRS”) on the tax consequences of these transactions. An opinion of counsel is not binding on the IRS or the courts, which may disagree with the opinion. Even if the merger and exchange offer otherwise qualified as tax-free transactions, they may become taxable to us if certain events occur that affect either Ecolab or ChampionX Corporation. While ChampionX Corporation has agreed not to take certain actions that could cause the transactions not to qualify as tax-free transactions and is generally obligated to indemnify us against any tax consequences if it breaches this agreement, the potential tax liabilities could have a material adverse effect on us if we were not entitled to indemnification or if the indemnification obligations were not fulfilled. If the merger or exchange offer were determined to be taxable, we could be subject to a substantial tax liability, and each U.S. holder of our common stock who participated in the exchange offer could be treated as exchanging the Ecolab shares surrendered for ChampionX Corporation shares in a taxable transaction.

Changes in tax laws and unanticipated tax liabilities could materially and adversely affect the taxes we pay and our profitability.

We are subject to income and other taxes in the United States and foreign jurisdictions, and our operations, plans and results are affected by tax and other initiatives around the world. We are also impacted by actions taken to tax-related matters by associations such as the Organization for Economic Co-operation and Development (“OECD”), which represents a coalition of member countries, and the European Commission which influence tax policies in countries where we operate. In particular, the OECD has coordinated negotiations among more than 140 jurisdictions with the goal of achieving consensus on various substantial changes to the international tax framework, including a 15% global minimum taxation regime (“Pillar Two”). Pillar Two took effect in several jurisdictions in which we operate starting in 2024 and will increase the burden and costs of our tax compliance. The enactment of the One Big Beautiful Bill Act (“OBBBA”) in the U.S. introduced changes to U.S. international tax provisions. These changes may interact with Pillar Two in complex ways. Statements by the Group of Seven Nations (“G7”) suggest a potential “side-by-side” framework that could exempt certain U.S. parented groups from all or certain aspects of Pillar Two rules but the final outcome remains uncertain. The evolving nature of these reforms may impact our tax profile, increase compliance costs, and create additional risks of double taxation or inconsistent treatment across jurisdictions. We continue to monitor Pillar Two legislative developments, which, based on information available, have not had material impacts on the 2025 financial statements. In addition, we are impacted by settlements of pending or any future adjustments proposed by the IRS or other taxing authorities in connection with our tax audits, all of which will depend on their timing, nature and scope. Increases in income tax rates, changes in income tax laws or unfavorable resolution of tax matters could have a material adverse impact on our financial results.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes significant provisions, such as permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. An estimate of the financial impact has been included in operating results as of December 31, 2025. While we expect certain provisions of OBBBA to change the timing of U.S. cash taxes related to the current and future periods, OBBBA did not have a material impact to the Company’s income tax expense.

Future events may impact our deferred tax position, including the utilization of foreign tax credits and undistributed earnings of international affiliates that are considered to be reinvested indefinitely.

We evaluate the recoverability of deferred tax assets and the need for deferred tax liabilities based on available evidence. This process involves significant management judgment about assumptions that are subject to change from period to period based on changes in tax laws or variances between future projected operating performance and actual results. We are required to establish a valuation allowance for deferred tax assets if we determine, based on available evidence at the time the determination is made, that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making this determination, we evaluate all positive and negative evidence as of the end of each reporting period. Future adjustments (either increases or decreases), to the deferred tax asset valuation allowance are determined based upon changes in the expected realization of the net deferred tax assets. The realization of the deferred tax assets ultimately depends on the existence of sufficient taxable income in either the carry-back or carry-forward periods under the tax law. Due to significant estimates used to establish the valuation allowance and the potential for changes in facts and circumstances, it is reasonably possible that we will be required to record adjustments to the valuation allowance in future reporting periods. Changes to the valuation allowance or the amount of deferred tax liabilities could have a material adverse effect on our consolidated results of operations or financial position. Further, should we change our assertion regarding the permanent reinvestment of the undistributed earnings of international affiliates, a deferred tax liability may need to be established.

Table of Contents

Our indebtedness may limit our operations and our use of our cash flow, and any failure to comply with the covenants that apply to our indebtedness could materially and adversely affect our liquidity and financial statements.

As of December 31, 2025, we had approximately $8.2 billion in outstanding indebtedness, with approximately $1.5 billion in the form of floating rate debt. Our debt level and related debt service obligations may have negative consequences, including:

●

requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt, which reduces the funds we have available for other purposes such as acquisitions and capital investment;

●

reducing our flexibility in planning for or reacting to changes in our business and market conditions;

●

exposing us to interest rate risk since a portion of our debt obligations are at variable rates. For example, a one percentage point increase in the average interest rate on our floating rate debt at December 31, 2025 would increase future interest expense by approximately $15 million per year; and

●

increasing our cost of funds and materially and adversely affecting our liquidity and access to the capital markets should we fail to maintain the credit ratings assigned to us by independent rating agencies.

If we add new debt, the risks described above could increase.

We incur significant expenses related to the amortization of intangible assets and may be required to report losses resulting from the impairment of goodwill or other assets recorded in connection with the Nalco, Purolite and Ovivo Electronics transactions and other acquisitions.

We expect to continue to complete selected acquisitions and joint venture transactions in the future. In connection with acquisition and joint venture transactions, applicable accounting rules generally require the tangible and intangible assets of the acquired business to be recorded on the balance sheet of the acquiring company at their fair values. Intangible assets other than goodwill are required to be amortized over their estimated useful lives and this expense may be significant. Any excess in the purchase price paid by the acquiring company over the fair value of tangible and intangible assets of the acquired business is recorded as goodwill. If it is later determined that the anticipated future cash flows from the acquired business may be less than the carrying values of the assets and goodwill of the acquired business, the assets or goodwill may be deemed to be impaired. In this case, the acquiring company may be required under applicable accounting rules to write down the value of the assets or goodwill on its balance sheet to reflect the extent of the impairment. This write-down of assets or goodwill is generally recognized as a non-cash expense in the statement of operations of the acquiring company for the accounting period during which the write down occurs. As of December 31, 2025, we had goodwill of $9.2 billion which is maintained in various reporting units, including goodwill from the Nalco, Purolite and Ovivo Electronics transactions. If we determine that any of the assets or goodwill recorded in connection with the Nalco, Purolite, and Ovivo Electronics transactions or any other prior or future acquisitions or joint venture transactions have become impaired, we will be required to record a loss resulting from the impairment. Impairment losses could be significant and could have a material adverse effect on our consolidated results of operations and financial position.

Item 1B. Unresolved Staff Comments.

None.

Item 1C. Cybersecurity.

Since 2014, when the Ecolab Cybersecurity program was established, we have continuously matured our cybersecurity program to proactively address evolving cybersecurity trends and risks. Ecolab has an Information Security Steering Committee (“ISSC”), a cross-functional team chaired by our Chief Information Security Officer (“CISO”).

Our CISO, who holds a CISO certification, has been our CISO since 2024 and has more than 25 years of information systems experience in total, including in the financial services and defense sectors and the U.S. military, as well as serving in information security and other information technology leadership positions at Ecolab since 2017.

Senior management provides in-depth reviews of cybersecurity matters to the Board and the Audit Committee. Cybersecurity is also considered in the annual enterprise risk assessment presented to the Board by management as part of the Board’s oversight of our enterprise risk management (“ERM”) program.

Ecolab’s cybersecurity policies, standards, processes, and practices are integrated into our ERM program and are based on recognized frameworks established by the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”), the International Organization for Standardization and other applicable industry standards. We are formally assessed by an independent third party against NIST CSF and industry standards, including peer benchmarking.

Risk Management and Strategy

Cybersecurity presents strategic and operating risks and is an area of continued focus for our Board and management under its ERM program. Ecolab’s cybersecurity program addresses the following key areas:

●

Governance: As discussed in more detail under the heading “Cybersecurity Governance,” the Audit Committee and the Board of Directors provide oversight of cybersecurity risk management.

Table of Contents

●

Technical Safeguards: We have implemented multi-layer controls designed to protect our information systems from cybersecurity threats, including general, backup, recovery, resiliency, processing, access, change and risk controls. These controls are evaluated by Ecolab’s cybersecurity team and enhanced through controls audits and assessments, internal testing, and third-party cybersecurity threat intelligence.

●

Incident Response and Recovery Planning: We have established and maintain comprehensive cybersecurity incident response and recovery plans that coordinate multidisciplinary internal teams and cybersecurity partners to assess, triage, escalate, contain, mitigate, investigate, remediate, and recover from a potential cybersecurity incident. Through ongoing communications with these teams, management monitors the incidents and reports incidents to the Audit Committee when appropriate. Management is responsible for timely disclosure of cybersecurity incidents as required by law.

●

Third-Party Risk Management: We maintain a risk-based approach to identify, monitor, and manage third-party cybersecurity risks associated with our use of third-party service providers who have access to our systems, data or are critical to our continued business operations. Additionally, cybersecurity considerations affect the selection and oversight of our third-party service providers. We require certain third-party vendors to agree to manage their cybersecurity risks in specified ways, and to agree to be subject to cybersecurity audits, which we conduct as appropriate.

●

Education and Awareness: We provide training for personnel regarding cybersecurity trends and threats to equip them with the knowledge to recognize and tools to report suspected cybersecurity threats. We also conduct simulations for employees and contractors to enhance awareness and responsiveness to such possible threats. In addition, we send global cybersecurity awareness communications to our personnel.

●

Assessment: We engage in the periodic assessment, testing and updating of our policies, standards, processes, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures, and planning. We engage third parties to perform assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. Additionally, we leverage third party cybersecurity rating agency data to inform our assessment of risk. The results of such assessments, audits and reviews are reported to the Audit Committee and the Board.

While we have continually matured our security program and capabilities and have had no material incidents to date, cyber threats continue to evolve and there can be no assurance that our efforts will prevent cybersecurity attacks or breaches in our systems such as those described in the risk factor entitled, “We are subject to information technology system failures, network disruptions and breaches in data security” under “Item 1A. Risk Factors” of this Form 10-K.

Cybersecurity Governance

Ecolab’s ISSC, chaired by our CISO, meets regularly and as needed. The Committee is comprised of executive leaders including the Executive Vice President and General Manager - Ecolab Digital (“EVP & GM Digital”), the Senior Vice President IT Enterprise Operations, the Chief Operating Officer, the Chief Financial Officer, the Chief Technical Officer, the General Counsel, the Executive Vice Presidents of our commercial divisions, the Executive Vice President Global Supply Chain, the Executive Vice President Human Resources, the Senior Vice President of Global Business Services, and the Vice President Audit Services.

The ISSC assists the CISO in fulfilling our responsibilities regarding our information security program to protect the confidentiality, integrity and availability of our information assets, financial assets, and information systems. ISSC responsibilities include, but are not limited to, evaluation of relevant information security risks, prioritization of information security initiatives, determination of, and advocacy for, appropriate investments, review of related legal and regulatory compliance initiatives, review of effective security communication initiatives, establishing specific requirements of the program in documented policies which all Ecolab associates, customers, and partners are obligated to follow, partner with Ecolab’s business, functional and regional leaders to ensure effective, risk-based security controls and practices are in place to achieve the program’s intent, and assist in monitoring the integrity and evaluating the effectiveness of the program.

The Board, in coordination with the Audit Committee, provides oversight of our ERM program, including the management of risks arising from cybersecurity threats. The Board receives an overview and the Audit Committee receives reports from our CISO regarding our cybersecurity threat risk management and strategy processes. These reports cover a wide range of topics, and may include current and emerging cybersecurity threat risks, third-party assessments, risk-mitigation tactics and programs, information security considerations arising with respect to our peers and third parties, and our incident response plan.

Through a risk-based approach consistent with Ecolab’s ERM framework, the CISO identifies cyber incidents that are brought forward to a cross-functional cyber-incident response team including our CEO, CFO, EVP & GM Digital, General Counsel, CISO and Executive Vice President Supply Chain. This cyber incident response team, or, in the event of more minor incidents, the CISO and his team, takes steps to promptly assess and address the incident, including engaging third parties according to pre-established guidelines. The Board and the Audit Committee also receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, including ongoing updates regarding any such incident until it has been addressed.

Table of Contents

Item 2. Properties.

We operate 30 manufacturing facilities in 13 states in the U.S. Internationally, we operate 70 manufacturing facilities in 39 countries. We own most of our manufacturing locations. Our manufacturing philosophy is to manufacture products wherever an economic, process or quality assurance advantage exists or where proprietary manufacturing techniques dictate in-house production. Currently, most products that we sell are manufactured at our facilities. We position our manufacturing locations and warehouses in a manner to permit ready access to our customers. In general, manufacturing facilities located in the United States serve our U.S. markets and facilities located outside of the United States serve our international markets. However, most of the United States facilities do manufacture products for export. Many of our properties are used by multiple segments.

Our manufacturing facilities produce chemical products and equipment for all our operating segments, although Pest Elimination purchases the majority of their products and equipment from outside suppliers. Our chemical production process consists of blending purchased raw materials into finished products in powder, liquid, and solid form. Additionally, intermediates from reaction chemistries are used in some of the blends and are also packaged directly into finished goods. Our devices and equipment manufacturing operations consist of producing chemical product dispensers and injectors and other mechanical equipment, medical devices, dishwasher racks, related sundries, dish machine refurbishment and water monitoring and maintenance equipment system from purchased components and subassemblies.

Generally, our manufacturing facilities are adequate to meet our existing in-house production needs. We continue to invest in our plant sites to maintain viable operations and to add capacity as necessary to meet business imperatives.

Most of our manufacturing plants also serve as distribution centers. In addition, we operate distribution centers around the world, most of which are leased, and utilize third party logistics service providers to facilitate the distribution of our products and services.

Our corporate headquarters is comprised of a 17-story building that we own in St. Paul, Minnesota. We also own a 115-acre campus in Eagan, Minnesota that houses a significant research and development center and training facilities as well as several of our administrative functions. We also have a significant business presence in Naperville, Illinois, where our Light & Heavy and Paper operating segments maintain their principal administrative offices and research center, as well as in Greensboro, North Carolina, where our Specialty operating segment maintains its principal administrative offices and a research center. Our Light & Heavy operating segment leases administrative and research facilities in Houston, Texas. Our Life Sciences operating segment maintains leased and owned facilities in the greater King of Prussia, PA area for administrative functions, and research and development.

Significant regional administrative and/or research facilities are located in Campinas, Brazil; Leiden, Netherlands, which we own; and in Bangalore, India; Dubai, UAE; Monheim, Germany; Pune, India; Singapore; Shanghai, China; and Zurich, Switzerland, which we lease. We also have a limited network of small, leased sales offices throughout the world.

Item 3. Legal Proceedings.

Discussion of legal proceedings is incorporated by reference from Part II, Item 8, Note 15, “Commitments and Contingencies,” of this Form 10-K and should be considered an integral part of Part I, Item 3, “Legal Proceedings.”

Discussion of other environmental-related legal proceedings is incorporated by reference from Part I, Item 1 above, under the heading “Environmental and Regulatory Considerations.”

In accordance with 17 CFR § 229.103(c)(iii)(3), we have established a threshold of $1 million for reporting potential monetary sanctions relating to administrative or judicial proceedings brought by a governmental authority under any Federal, State, or local provisions that have been enacted or adopted regulating the discharge of materials into the environment or primarily for the purpose of protecting the environment. We have no such proceedings exceeding this threshold to report.

Item 4. Mine Safety Disclosures.

Not applicable.

Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is listed on the New York Stock Exchange under the symbol “ECL.” Our common stock is also traded on an unlisted basis on certain other United States exchanges.

Dividends

Dividends declared per common share in 2025 were $2.68 per share. In December 2025, we increased our quarterly cash dividend by 12% to $0.73 per share, representing our 34th consecutive annual dividend rate increase. We have paid cash dividends on our common shares for 89 consecutive years. Our outstanding dividend history reflects our long-term growth and development, strong cash flows, solid financial position and confidence in our business prospects for the years ahead.

Holders

On January 30, 2026, we had 4,333 holders of record of our Common Stock.

Issuer Purchases of Equity Securities


				Total number of shares	Maximum number of
				purchased as part of	shares that may yet be
	Total number of	Average price paid		publicly announced	purchased under the
Period	shares purchased	per share		plans or programs (1)	plans or programs (1)
October 1-31, 2025	241,240		$274.2840	241,240	7,170,389
November 1-30, 2025	951,977		260.9840	951,977	6,218,412
December 1-31, 2025	321,591		264.7744	321,591	5,896,821
Total	1,514,808		$263.9068	1,514,808	5,896,821

(1)

As announced on November 3, 2022, our Board of Directors authorized the repurchase of up to 10,000,000 common shares. Subject to market conditions, we expect to repurchase all shares under this authorization, for which no expiration date has been established, in open market or privately negotiated transactions, including pursuant to Rule 10b5-1 and accelerated share repurchase programs.

Item 6. [Reserved].

Table of Contents

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following management discussion and analysis (“MD&A”) provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative or qualitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The discussion should be read in conjunction with the consolidated financial statements and related notes included in this Form 10-K. Our consolidated financial statements are prepared in accordance with U.S. GAAP. This discussion contains various Non-GAAP Financial Measures and also contains various forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements and information set forth in the sections entitled “Non-GAAP Financial Measures” at the end of this MD&A, and “Forward-Looking Statements” and “Risk Factors” within Items 1 and 1A of this Form 10-K. We also refer readers to the tables within the section entitled “Results of Operations” of this MD&A for reconciliation information of Non-GAAP measures to U.S. GAAP.

Comparability of Results

Ovivo Electronics Acquisition

On December 16, 2025, we acquired Ovivo’s electronics business (“Ovivo Electronics”) for total consideration of $1.6 billion in cash. Ovivo Electronics is a leading and fast-growing global provider of breakthrough ultrapure water technologies for semiconductor manufacturing. Ovivo Electronics is reported within our Light & Heavy operating segment. Acquisition and integration charges are recorded within special (gains) and charges. The remaining impacts of the Ovivo Electronics acquisition, including operating results, acquisition-related amortization and interest expense related to the transaction, have also been excluded from adjusted results.

Impact of Acquisitions and Divestitures

Our non-GAAP financial measures for organic sales, organic operating income and organic operating income margin are at fixed currency and exclude the impact of special (gains) and charges, the results of our acquired businesses from the first twelve months post acquisition and the results of divested businesses from the twelve months prior to divestiture. In addition, as part of the separation of ChampionX in 2020, we continue to provide certain products to ChampionX which are recorded in product and equipment sales in the Global Water segment along with the related cost of sales. Further, due to the sale of the global surgical solutions business on August 1, 2024, we have excluded the results of that business for January through July 2024 from these organic measures for the year ended December 31, 2024 to remain comparable to the corresponding period in 2025. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

Comparability of Reportable Segments

Effective January 1, 2025, the Company’s former Global Industrial reportable segment was renamed Global Water and includes the Light & Heavy (previously named Water), Food & Beverage, and Paper operating segments. The Global Institutional & Specialty reportable segment continues to include the Institutional and Specialty operating segments. The Company’s former healthcare operating segment moved into the Institutional operating segment. Global Life Sciences was elevated to a standalone reportable segment. The Global Pest Elimination segment remains a standalone reportable segment. After these changes, the Company has seven operating segments.

Fixed Currency Foreign Exchange Rates

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

Table of Contents

EXECUTIVE SUMMARY

In 2025, we delivered record sales, operating income margin, adjusted diluted earnings per share, and free cash flows. Our team generated strong organic sales growth in Global Pest Elimination and Global Life Sciences, and good organic sales growth in Global Institutional & Specialty and Global Water. Organic operating income grew by double digits, as strong value pricing and improved productivity were partially offset by investments in the business.

Sales

Reported sales increased 2% to $16.1 billion in 2025 from $15.7 billion in 2024. When measured in fixed rates of foreign currency exchange, fixed currency sales increased 2% compared to the prior year. Organic sales increased 3% compared to the prior year.

Gross Margin

Our reported gross margin was 44.5% of sales for 2025, compared to our 2024 reported gross margin of 43.5%. Excluding the impact of special (gains) and charges and the Ovivo Electronics acquisition included in cost of sales, our adjusted gross margin was 44.5% in 2025 and 43.5% in 2024. Our gross margin increase reflected strong value pricing.

Operating Income

Reported operating income decreased 2% to $2.7 billion in 2025, compared to $2.8 billion in 2024. Adjusted operating income, excluding the impact of special (gains) and charges and the Ovivo Electronics acquisition increased 11% in 2025 as strong value pricing and improved productivity were partially offset by investments in the business. Organic operating income increased 13% in 2025.

Earnings Attributable to Ecolab Per Common Share (“EPS”)

Reported diluted EPS decreased 1% to $7.28 in 2025, compared to $7.37 in 2024. Special (gains) and charges had an impact on both years. Special (gains) and charges in 2025 were primarily related to One Ecolab, while in 2024 they were driven primarily by the gain on sale of the global surgical solutions business and restructuring expense. Adjusted diluted EPS, which excludes the impact of special (gains) and charges, discrete tax items and the Ovivo Electronics acquisition increased 13% to $7.53 in 2025 compared to $6.65 in 2024 which reflected good organic sales growth and robust operating income margin expansion.

Balance Sheet

We remain committed to maintaining “A” range ratings metrics over the long-term, supported by our current credit ratings of A-/A3/A- by Standard & Poor’s, Moody’s Investor Services and Fitch, respectively. Our strong balance sheet has allowed us continued access to capital at attractive rates.

Cash Flow

Cash flow from operating activities was $3.0 billion in 2025, compared to $2.8 billion in 2024. We continued to generate strong cash flow from operations, allowing us to fund our ongoing operations, investments in our business, acquisitions, debt repayments, pension obligations and return cash to our shareholders through share repurchases and dividend payments.

Dividends

Dividends declared per common share in 2025 were $2.68 per share. In December 2025 we increased our quarterly cash dividend by 12% to $0.73 per share, representing our 34^th consecutive annual dividend rate increase. We have paid cash dividends on our common shares for 89 consecutive years. Our outstanding dividend history reflects our long-term growth and development, strong cash flows, solid financial position and confidence in our business prospects for the years ahead.

Table of Contents

CRITICAL ACCOUNTING ESTIMATES

Our consolidated financial statements are prepared in accordance with U.S. GAAP. We have adopted various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 2, “Significant Accounting Policies,” of the Notes to the Consolidated Financial Statements (“Notes”).

Preparation of our consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are considered to be critical if they involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations.

Besides estimates that meet the “critical” estimate criteria, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues or expenses as well as disclosures of contingent assets and liabilities. Estimates are based on experience and other information available prior to the issuance of the financial statements. Materially different results can occur as circumstances change and additional information becomes known, even from estimates not deemed critical. Our critical accounting estimates include the following:

Actuarially Determined Liabilities

Pension and Postretirement Healthcare Benefit Plans

The measurement of our pension and postretirement benefit obligations are dependent on a variety of assumptions determined by management and used by our actuaries in their valuations and calculations. These assumptions affect the amount and timing of future pension contributions, benefit payments and expense or income recognized.

The significant assumptions used in developing the required estimates are the discount rates, expected returns on assets and projected salary and health care cost increases.

●

The discount rate assumptions for our U.S. plans are assessed using a yield curve constructed from a subset of bonds yielding greater than the median return from a population of non-callable, corporate bonds that have an average rating of AA when averaging available Moody’s Investor Services, Standard & Poor’s and Fitch ratings. The discount rates are calculated by matching each plans’ projected cash flows to the bond yield curve. For 2025 and 2024, we measured service and interest costs by applying the specific spot rates along that yield curve to the plans’ liability cash flows. We believe this approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. In determining our U.S. pension obligations and U.S. postretirement health care obligation for 2025, our weighted-average discount rate decreased to 5.28% from 5.58% at year-end 2024.

●

The expected rate of return on plan assets reflects asset allocations, investment strategies and views of investment advisors, and represents our expected long-term return on plan assets. Our weighted-average expected returns on U.S. plan assets used in determining the U.S. pension and U.S. postretirement health care expenses was 8.25% for 2025, 8.00% for 2024, and 7.75% for 2023.

●	Projected salary is based on our long-term actual experience, the near-term outlook and assumed inflation. Our weighted-average projected salary increase used in determining the U.S. pension expenses was 3.60% for 2025, 3.60% for 2024, and 4.03% for 2023.

●

For postretirement benefit measurement purposes as of December 31, 2025, the annual rates of increase in the per capita cost of covered health care were assumed to be 8.15% for pre-65 costs. Post-65 costs are no longer used. The rates are assumed to decrease each year until they reach 4.5% in 2035 and remain at those levels thereafter.

The effects of actual results differing from our assumptions, as well as changes in assumptions, are reflected in the unrecognized gains or losses and amortized into earnings in the future. Significant differences in actual experience or significant changes in assumptions may materially affect future pension and other postretirement obligations and income or expense. The unrecognized net losses on our U.S. qualified and non-qualified pension plans decreased to $486 million as of December 31, 2025, from $526 million as of December 31, 2024 (both before tax), primarily due to higher actual return on assets.

Table of Contents

The effect of a decrease in the discount rate or in the expected return on assets assumption as of December 31, 2025, on the December 31, 2025 defined benefit obligation and 2026 expense is shown below, assuming no changes in benefit levels. Expense amounts reflect the accounting for gains or losses as a component of other comprehensive income or expense and recognition of the impacts into earnings over time:


	Effect on U.S. Pension Plans
		Increase in		Higher
	Assumption	Recorded		2026
(millions)	Change	Obligation		Expense
Discount rate	0.25 pts		$33.1		$2.5
Expected return on assets	0.25 pts		N/A		4.4


	Effect on U.S. Postretirement
	Health Care Benefits Plans
		Increase in		Higher
	Assumption	Recorded		2026
(millions)	Change	Obligation		Expense
Discount rate	0.25 pts		$1.9		$-
Expected return on assets	0.25 pts		N/A		-

Our international pension obligations and underlying plan assets represent approximately one third of our global pension plans, with the majority of the amounts held in the U.K. and Eurozone countries. We use assumptions similar to our U.S. plan assumptions to measure our international pension obligations, however, the assumptions used vary by country based on specific local country requirements and information.

Refer to Note 16, “Retirement Plans,” of the Notes for further discussion concerning our accounting policies, estimates, funded status, contributions and overall financial positions of our pension and postretirement plan obligations.

Self-Insurance

Globally we have insurance policies with varying deductible levels for property and casualty losses. We are insured for losses in excess of these deductibles, subject to policy terms and conditions and have recorded both a liability and an offsetting receivable for amounts in excess of these deductibles. We are self-insured for health care claims for eligible participating employees, subject to certain deductibles and limitations. We determine our liabilities for claims on an actuarial basis.

Income Taxes

Judgment is required to determine the annual effective income tax rate, deferred tax assets and liabilities, valuation allowances recorded against net deferred tax assets and unrecognized tax benefits.

Effective Income Tax Rate

Our effective income tax rate is based on annual income, statutory tax rates and tax planning available in the various jurisdictions in which we operate. Our annual effective income tax rate includes the impact of unrecognized tax benefits. We recognize the amount of tax benefit that is greater than 50% likely of being realized upon settlement with a taxing authority. We adjust these liabilities for unrecognized tax benefits in light of changing facts and circumstances.

Tax regulations require items to be included in our tax returns at different times than the items are reflected in our financial statements. As a result, the effective income tax rate reflected in our financial statements differs from statutory tax rates. Some of these differences are permanent, such as expenses that are not deductible on our tax return, and some are temporary differences, such as depreciation expense.

Deferred Tax Assets and Liabilities and Valuation Allowances

Deferred tax assets and liabilities are determined based on temporary differences between the financial reporting and tax bases of assets and liabilities, applying enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Based on the evaluation of available evidence, both positive and negative, we recognize tax assets, such as net operating loss carryforwards and tax credit carryforwards, to the extent that realizing these benefits is considered to be more likely than not. Relevant factors in determining the realizability of deferred tax assets include historical results, sources of future taxable income, the expected timing of the reversal of temporary differences, tax planning strategies and the expiration dates of the various tax attributes.

Table of Contents

Unrecognized Tax Benefits

A number of years may elapse before a particular tax matter, for which we have established a liability for unrecognized tax benefits, is audited and finally resolved. The number of tax years with open tax audits varies depending on the tax jurisdiction. The Internal Revenue Service (“IRS”) has completed examinations of our U.S. federal income tax returns through 2018 and the years 2019 through 2020 are currently under audit. In addition to the U.S. federal examinations, we have ongoing audit activity in several U.S. state and foreign jurisdictions.

The tax positions we take are based on our interpretations of tax laws and regulations in the applicable federal, state and international jurisdictions. We believe our tax returns properly reflect the tax consequences of our operations, and our liabilities for unrecognized tax benefits are appropriate and sufficient for the positions taken. Because of the uncertainty of the final outcome of these examinations, we have established a liability for potential reductions of tax benefits (including related interest and penalties) for amounts that do not meet the more-likely-than-not thresholds for recognition and measurement as required by authoritative guidance. The liability for unrecognized tax benefits is reviewed throughout the year, taking into account new legislation, regulations, case law and audit results. Settlement of any particular issue could result in offsets to other balance sheet accounts, cash payments or receipts and/or adjustments to tax expense. Liabilities for unrecognized tax benefits are presented in the Consolidated Balance Sheets within other non-current liabilities. Our gross liability for unrecognized tax benefits was $53.9 million and $34.1 million as of December 31, 2025 and 2024, respectively. For additional information on income taxes refer to Note 12, “Income Taxes,” of the Notes.

Long-Lived Assets, Intangible Assets and Goodwill

Long-Lived and Amortizable Intangible Assets

Purchased long-lived and amortizable intangible assets not acquired as part of a business combination are recorded as of their acquisition date at cost, whereas long-lived and amortizable assets acquired as part of a business combination are recorded as of their acquisition date at their fair values based on the fair value requirements defined in U.S. GAAP. This requires us to make significant estimates and assumptions relating to the present value of its future cash flows, such as growth rates, royalty rates or discount rates.

We review our long-lived and amortizable intangible assets, the net value of which was $7.5 billion and $6.5 billion as of December 31, 2025 and 2024, respectively, for impairment when significant events or changes in business circumstances indicate that the carrying amount of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset or asset group, a significant adverse change in the manner in which asset or asset groups are being used or history of operating or cash flow losses associated with the use of the asset or asset group. Impairment losses could occur when the carrying amount of an asset or asset group exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset or asset group and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated as the excess of the asset’s or assets group’s carrying amount over its estimated fair value.

We use the straight-line method to recognize amortization expense related to our amortizable intangible assets, including our customer relationships. We consider various factors when determining the appropriate method of amortization for our customer relationships, including projected sales data, customer attrition rates and length of key customer relationships.

Globally, we have a broad customer base. Our retention rate of significant customers has aligned with our acquisition assumptions, including the customer bases acquired from our Nalco, Laboratoires Anios (“Anios”), Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), Purolite and Ovivo Electronics transactions, which make up the majority of our unamortized customer relationships. Our historical retention rates, coupled with our consistent track record of keeping long-term relationships with our customers, support our expectation of consistent sales generation for the foreseeable future from the acquired customer bases. If our customer retention rates or other post-acquisition operational activities change materially, we would evaluate the financial impacts and significance of the events given rise to the change which could result in impairment of our customer relationship intangible assets, or absent an impairment, an acceleration of amortization expense.

In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would impact the amount of depreciation and amortization expense recorded in earnings. We have experienced no significant changes in the carrying amount or estimated remaining useful lives of our long-lived or amortizable intangible assets.

Table of Contents

Goodwill and Indefinite Life Intangible Assets

Goodwill arises from our acquisitions and represents the excess of the fair value of the purchase consideration exchanged over the fair value of net assets acquired. We had total goodwill of $9.2 billion and $7.9 billion as of December 31, 2025 and 2024, respectively. We test our goodwill for impairment at the reporting unit level. Our reporting units are our seven operating segments. We assess goodwill for impairment on an annual basis during the second quarter. If circumstances change or events occur that demonstrate it is more likely than not that the carrying amount of a reporting unit exceeds its fair value, we complete an interim goodwill impairment assessment of that reporting unit prior to the next annual assessment. If the results of an annual or interim goodwill impairment assessment demonstrate the carrying amount of a reporting unit is greater than its fair value, we will recognize an impairment loss for the amount by which the reporting unit’s carrying amount exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit.

For our annual 2025 goodwill impairment assessment, we completed our impairment assessment for our seven reporting units using discounted cash flow analyses that incorporated assumptions regarding future growth rates, terminal values and discount rates. Our goodwill impairment assessments for 2025 indicated the estimated fair values of each of these seven reporting units exceeded the carrying amounts of the respective reporting units by a significant margin. No events were noted during the second half of 2025 that required completion of an interim goodwill impairment assessment in the second half of 2025 for any of our seven reporting units. There has been no impairment of goodwill in any of the periods presented.

The Nalco trade name is our only indefinite life intangible asset, which is tested for impairment on an annual basis during the second quarter. For our annual 2025 indefinite life intangible asset impairment assessment, we completed our impairment assessment of the Nalco trade name using the relief from royalty discounted cash flow method, which incorporates assumptions regarding future sales projections, royalty rates and discount rates. Our Nalco tradename impairment assessment for 2025 indicated the estimated fair value of the Nalco trade name exceeded its $1.2 billion carrying amount by a significant margin. No events were noted during the second half of 2025 that required completion of an interim impairment assessment of our Nalco trade name in the second half of 2025. There has been no impairment of the Nalco trade name intangible since it was acquired.

Table of Contents

RESULTS OF OPERATIONS

Net Sales


									Percent Change

(millions)	2025			2024		2023			2025		2024
Product and equipment sales		$12,618.5			$12,473.6		$12,316.8
Service and lease sales		3,462.7			3,267.8		3,003.4
Reported GAAP net sales		16,081.2			15,741.4		15,320.2		2	%	3	%
Impact of Ovivo Electronics on net sales		(3.7)			-		-
Non-GAAP adjusted net sales		16,077.5			15,741.4		15,320.2		2	%	3	%
Effect of foreign currency translation		(514.0)			(468.0)		(519.2)
Non-GAAP adjusted fixed currency sales		15,563.5			15,273.4		14,801.0		2	%	3	%
Effect of acquisitions and divestitures		(87.2)			(248.4)		*
Non-GAAP organic sales		$15,476.3			$15,025.0		*		3	%	*
* Not meaningful

The percentage components of the year-over-year sales change are shown below:


(percent)	2025			2024
Volume		1	%		*	%
Price changes		2			*
Organic sales change		3			*
Acquisitions and divestitures		(1)			*
Fixed currency sales change		2			3
Foreign currency translation		-			-
Reported GAAP net sales change		2	%		3	%
* Not meaningful

Amounts do not necessarily sum due to rounding.

Cost of Sales (“COS”) and Gross Profit Margin (“Gross Margin”)


	2025				2024				2023
			Gross				Gross				Gross
(millions/percent)		COS	Margin			COS	Margin			COS	Margin
Product and equipment cost of sales		$6,955.8				$6,990.0				$7,389.2
Service and lease cost of sales		1,975.0				1,909.7				1,765.7
Reported GAAP COS and gross margin		8,930.8	44.5	%		8,899.7	43.5	%		9,154.9	40.2	%
Special (gains) and charges		7.7				5.3				22.5
Impact of Ovivo Electronics on COS		3.5				-				-
Non-GAAP adjusted COS and gross margin		$8,919.6	44.5	%		$8,894.4	43.5	%		$9,132.4	40.4	%

Our COS values and corresponding gross margin are shown above. Our gross margin is defined as sales less cost of sales divided by sales.

Our reported gross margin was 44.5%, 43.5%, and 40.2% for 2025, 2024, and 2023, respectively. Our 2025, 2024 and 2023 reported gross margins were negatively impacted by special (gains) and charges of $7.7 million, $5.3 million, and $22.5 million, respectively. Special (gains) and charges items impacting COS are shown within the “Special (Gains) and Charges” table below.

Excluding the impact of special (gains) and charges and the Ovivo Electronics acquisition, our 2025 adjusted gross margin was 44.5% compared against a 2024 adjusted gross margin of 43.5%. Our adjusted gross margin increased when comparing 2025 against 2024 reflecting strong value pricing.

Excluding the impact of special (gains) and charges, our adjusted gross margin was 43.5% and 40.4% for 2024 and 2023, respectively. The increase primarily reflected strong value pricing and lower delivered product costs.

Table of Contents

Selling, General and Administrative Expenses (“SG&A”)


(percent)		2025		2024		2023
SG&A Ratio		26.5	%	26.9	%	26.5	%

The decreased SG&A ratio (SG&A expenses as a percentage of reported net sales) comparing 2025 against 2024 was driven by productivity which was partially offset by growth-oriented investments in the business. The increased SG&A ratio (SG&A expenses as a percentage of reported net sales) comparing 2024 against 2023 was driven by growth-oriented investments in the business which was partially offset by sales productivity.

Special (Gains) and Charges

Special (gains) and charges reported on the Consolidated Statements of Income included the following items:



(millions)	2025		2024		2023
Cost of sales
One Ecolab		$7.7		$1.9		$-
Other restructuring		-		3.4		22.5
Cost of sales subtotal		7.7		5.3		22.5

Special (gains) and charges
One Ecolab		140.2		98.3		-
Other restructuring		(12.0)		21.8		63.2
Sale of global surgical solutions business		3.0		(340.3)		10.3
Acquisition and integration activities		36.1		12.6		16.1
Other		(12.4)		18.7		21.8
Special (gains) and charges subtotal		154.9		(188.9)		111.4

Total special (gains) and charges		$162.6		($183.6)		$133.9

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting. Per share amounts do not necessarily sum due to rounding.

One Ecolab

On July 30, 2024, we announced the One Ecolab initiative, which will enhance our growth and margin expansion journey. As a program within this initiative, we also announced that we commenced a restructuring plan to leverage our digital technologies to realign the functional work done in many countries into global centers of excellence. In February 2026, we expanded the One Ecolab initiative and anticipate total restructuring costs of $334 million ($261 million after tax) or $0.91 per diluted share and special charges of $91 million ($71 million after tax) or $0.25 per diluted share by the end of 2027. We anticipate that the restructuring costs will primarily be cash expenditures for severance costs relating to team realignment. We also expanded the estimated annualized cost savings to $325 million in continuing operations by 2027. One Ecolab has delivered $119 million of cumulative cost savings.

In anticipation of the One Ecolab initiative, a limited number of actions were taken in the first and second quarter of 2024. As a result, we reclassified $5.3 million ($4.0 million after tax) or $0.01 per diluted share from other restructuring to One Ecolab in the third quarter of 2024.

We recorded restructuring charges of $117.0 million ($90.5 million after tax), or $0.32 per diluted share and $76.5 million ($59.0 million after tax), or $0.21 per diluted share in 2025 and 2024, respectively, primarily related to severance and professional services. In addition, we recorded non-restructuring special charges of $30.9 million ($23.4 million after tax), or $0.08 per diluted share and $23.7 million ($17.9 million after tax), or $0.06 per diluted share in 2025 and 2024, respectively, primarily related to professional services. We have recorded $198.8 million ($153.5 million after tax), or $0.54 per diluted share of cumulative restructuring charges and $54.6 million ($41.3 million after tax), or $0.14 per diluted share of cumulative special charges under the One Ecolab initiative. Net cash payments were $75.8 million during 2025 and $26.9 million in 2024.

The net restructuring liability related to the One Ecolab initiative was $96.1 million and $54.9 million as of December 31, 2025 and 2024, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

Table of Contents

Other restructuring

Other restructuring is primarily related to the Combined Program which is described below. These activities have been included as a component of cost of sales and special (gains) and charges on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

Further details related to our restructuring charges are included in Note 3, “Special (Gains) and Charges,” of the Notes.

In November 2022, we approved a Europe cost savings program and subsequently expanded the program to focus on our Institutional and Healthcare businesses in other regions (the “Combined Program”). The restructuring activities were completed at the end of 2024, with total costs of $184.1 million ($151.5 million after tax), or $0.53 per diluted share. Subsequent to the completion of the Combined Program, we finalized the sale of a facility, resulting in a gain of $12.0 million ($9.2 million after tax), or $(0.03) per diluted share in the second quarter of 2025.

In 2024 and 2023, we recorded restructuring (gains) charges of $25.2 million ($18.6 million after tax) or $0.06 per diluted share, and $77.7 million ($66.4 million after tax), or $0.23 per diluted share, respectively, primarily related to severance and professional services in the Combined Program.

We reclassified $5.3 million ($4.0 million after tax), or $0.01 per diluted share from the combined restructuring program to other restructuring activities in the second quarter of 2024.

During 2024, we recorded restructuring charges of $10.6 million ($8.0 million after tax), or $0.03 per diluted share related to an immaterial restructuring plan approved in the second quarter of 2024. This plan became part of the One Ecolab initiative in the third quarter of 2024.

During 2023, we recorded restructuring charges of $8.0 million ($6.0 million after tax), or $0.03 per diluted share related to immaterial or subsequently concluded restructuring programs. The charges were primarily related to severance and asset write-offs.

The restructuring liability balance for all other restructuring plans excluding the One Ecolab Program was $8.8 million and $19.3 million as of December 31, 2025 and 2024, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. Cash payments during 2025 related to all other restructuring plans excluding the One Ecolab Program was $10.4 million.

Sale of global surgical solutions business

On April 27, 2024, we reached a definitive agreement to sell our global surgical solutions business, which closed on August 1, 2024. During 2024, we recorded a gain on sale of $355.9 million ($257.7 million after tax) or ($0.90) per diluted share, as described in Note 4, “Acquisitions and Dispositions,” of the Notes. During 2025, we recorded charges of $3.0 million ($2.3 million after tax) or $0.01 per diluted share, which are primarily related to professional fees to support the sale. Excluding the gain on sale, we recorded charges of $15.6 million ($12.0 million after tax), or $0.05 per diluted share in 2024, which are primarily related to professional fees to support the sale. During 2023, we recorded charges of $10.3 million ($7.7 million after tax) or $0.03 per diluted share, primarily related to professional fees to support the sale.

Acquisition and integration related costs

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2025 include $36.1 million ($31.2 million after tax), or $0.11 per diluted share, primarily related to the Ovivo Electronics and Purolite transactions.

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2024 and 2023 include $12.6 million ($9.6 million after tax) or $0.03 per diluted share and $16.1 million ($12.0 million after tax), or $0.04 per diluted share, respectively, primarily related to the Purolite transaction.

Other operating activities

During 2025, we recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of ($12.4 million) ($10.8 million gain after tax), or ($0.04) per diluted share, relating primarily to the sale of an equity method investment.

During 2024, we recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of $18.7 million ($13.9 million after tax), or $0.05 per diluted share, relating primarily to a liability relating to a prior divestiture, COVID-19 activities, and certain legal charges. During 2023, we recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of $21.8 million ($16.7 million after tax), or $0.05 per diluted share, relating primarily to certain legal charges.

Table of Contents

Operating Income and Operating Income Margin


											Percent Change

(millions)		2025			2024			2023			2025			2024
Reported GAAP operating income			$2,737.6			$2,802.4			$1,992.3			(2)	%		41	%
Special (gains) and charges			162.6			(183.6)			133.9
Impact of Ovivo Electronics on operating income			0.5			-			-
Non-GAAP adjusted operating income			2,900.7			2,618.8			2,126.2			11			23
Effect of foreign currency translation			(115.9)			(103.4)			(102.9)
Non-GAAP adjusted fixed currency operating income			2,784.8			2,515.4			2,023.3			11			24
Effect of acquisitions and divestitures			(10.6)			(52.7)			*
Non-GAAP organic operating income			$2,774.2			$2,462.7			*			13	%		*
* Not meaningful

(percent)		2025			2024			2023
Reported GAAP operating income margin			17.0	%		17.8	%		13.0	%
Non-GAAP adjusted operating income margin			18.0	%		16.6	%		13.9	%
Non-GAAP adjusted fixed currency operating income margin			17.9	%		16.5	%		13.7	%
Non-GAAP organic operating income margin			17.9	%		16.4	%		*
* Not meaningful

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by sales.

Our reported operating income was $2,737.6 million, $2,802.4 million, and $1,992.3 million, for 2025, 2024, and 2023, respectively. Our 2025, 2024 and 2023 operating incomes were negatively (positively) impacted by special (gains) and charges of $162.6 million, ($183.6 million) and $133.9 million, respectively.

Excluding the impacts of special (gains) and charges and the Ovivo Electronics acquisition, 2025 adjusted operating income increased 11% as strong value pricing and improved productivity were partially offset by investments in the business. Excluding the impacts of special (gains) and charges 2024 adjusted operating income increased 23% as strong value pricing, lower delivered product costs, and higher volumes were partially offset by investments in the business.

Other (Income) Expense


(millions)		2025		2024		2023
Reported GAAP other (income) expense			($51.4)		($51.3)		($59.9)

Our reported other income was $51.4 million, $51.3 million and $59.9 million, in 2025, 2024 and 2023, respectively. Other (income) expense was flat when comparing 2025 against 2024. Other (income) expense decreased when comparing 2024 against 2023 primarily due to higher pension costs.

Interest Expense, Net


(millions)		2025		2024		2023
Reported GAAP interest expense, net			$241.1		$282.5		$296.7
Impact of Ovivo Electronics on interest expense			3.6		-		-
Non-GAAP adjusted interest expense, net			$237.5		$282.5		$296.7

Our reported net interest expense totaled $241.1 million, $282.5 million, and $296.7 million during 2025, 2024, and 2023, respectively.

Adjusted for the Ovivo Electronics acquisition, the decrease in net interest expense when comparing 2025 against 2024 reflects the impact from lower interest rates and a higher cash balance. The decrease in interest expense when comparing 2024 against 2023 was driven primarily by lower interest expense from the repayment of our January 2024 note and the impact from higher interest income earned on cash balances driven by strong free cash flows and proceeds from the sale of the global surgical solutions business.

Table of Contents

Provision for Income Taxes

The following table provides a summary of our tax rate:


(percent)		2025		2024			2023
Reported GAAP tax rate		17.8	%	17.1	%		20.6	%
Tax rate impact of:
Special (gains) and charges		0.3		(1.1)			(0.1)
Discrete tax items		2.1		3.3			(0.6)
Ovivo Electronics tax impacts		-		-			-
Non-GAAP adjusted tax rate		20.2	%	19.3	%		19.9	%

Our reported tax rate was 17.8%, 17.1% and 20.6%, for 2025, 2024, and 2023, respectively. The change in our tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of our historical reported tax rates, as amounts included in our special (gains) and charges are derived from tax jurisdictions with rates that vary from our tax rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future.

We recognized a net tax benefit related to discrete tax items of $57.5 million during 2025. Discrete items include tax benefits of $21.5 million associated with recognition of deferred tax attributes and $16.8 million related to share-based compensation excess tax benefits. The remaining net discrete tax benefit of $19.2 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, and other changes in estimates.

We recognized a net tax benefit related to discrete tax items of $78.6 million during 2024. Discrete items include tax benefits of $62.1 million associated with a change to the tax classification of a wholly-owned non-US subsidiary that resulted in recognizing a capital loss and benefit of $30.4 million due to additional basis of foreign intangible assets. The remaining net discrete tax expense of $13.9 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, share-based compensation excess tax benefits, and other changes in estimates.

We recognized a net tax expense related to discrete tax items of $11.2 million during 2023. The net discrete tax expense was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, share-based compensation excess tax benefits and other changes in estimates.

The change in our adjusted tax rates from 2024 to 2025 was primarily driven by geographic income mix. Future comparability of our adjusted tax rate may be impacted by various factors, including but not limited to other changes in global tax rules, further tax planning projects and geographic income mix.

Net Income Attributable to Ecolab


										Percent Change

(millions)		2025			2024		2023			2025		2024
Reported GAAP net income attributable to Ecolab			$2,075.6			$2,112.4		$1,372.3		(2)	%	54	%
Adjustments:
Special (gains) and charges, after tax			127.4			(126.7)		109.2
Discrete tax net (benefit) expense			(57.5)			(78.6)		11.2
Impact of Ovivo Electronics on net income			3.1			-		-
Non-GAAP adjusted net income attributable to Ecolab			$2,148.6			$1,907.1		$1,492.7		13	%	28	%

Diluted EPS


										Percent Change

(dollars)		2025			2024		2023			2025		2024
Reported GAAP diluted EPS			$7.28			$7.37		$4.79		(1)	%	54	%
Adjustments:
Special (gains) and charges, after tax			0.45			(0.44)		0.38
Discrete tax net (benefit) expense			(0.21)			(0.28)		0.04
Impact of Ovivo Electronics on diluted EPS			0.01			-		-
Non-GAAP adjusted diluted EPS			$7.53			$6.65		$5.21		13	%	28	%

Per share amounts do not necessarily sum due to rounding.

Currency translation had a favorable $0.04 impact on reported and adjusted diluted EPS when comparing 2025 to 2024 and unfavorable ($0.09) impact when comparing 2024 to 2023.

Table of Contents

SEGMENT PERFORMANCE

The non-U.S. dollar functional currency international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates established by management for 2025. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2, “Significant Accounting Policies,” of the Notes. Additional information about our reportable segments is included in Note 18, “Operating Segment and Geographic Information,” of the Notes.

Fixed currency net sales and operating income for 2025, 2024 and 2023 for our reportable segments are shown in the following tables.


Net Sales									Percent Change

(millions)		2025		2024		2023			2025		2024
Global Water			$7,679.9		$7,483.4		$7,284.1		3	%	3	%
Global Institutional & Specialty			5,962.0		5,979.4		5,779.4		0		3
Global Pest Elimination			1,219.2		1,140.1		1,044.3		7		9
Global Life Sciences			706.1		670.5		650.8		5		3
Corporate			-		-		42.4		*		*
Subtotal at fixed currency			15,567.2		15,273.4		14,801.0		2		3
Effect of foreign currency translation			514.0		468.0		519.2
Consolidated reported GAAP net sales			$16,081.2		$15,741.4		$15,320.2		2	%	3	%

Operating Income									Percent Change

(millions)		2025		2024		2023			2025		2024
Global Water			$1,263.9		$1,207.2		$1,042.1		5	%	16	%
Global Institutional & Specialty			1,357.8		1,202.2		856.5		13		40
Global Pest Elimination			237.1		209.7		200.9		13		4
Global Life Sciences			120.7		91.8		118.9		31		(23)
Corporate			(353.2)		(12.1)		(329.0)		*		*
Subtotal at fixed currency			2,626.3		2,698.8		1,889.4		(3)		43
Effect of foreign currency translation			111.3		103.6		102.9
Consolidated reported GAAP operating income			$2,737.6		$2,802.4		$1,992.3		(2)	%	41	%

* Not meaningful

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

Year ended

December 31

Net Sales

2025

2024

(millions)

 

Fixed
Currency

Impact of Acquisitions and Divestitures

Organic

Fixed
Currency

Impact of Acquisitions and Divestitures

Organic

Global Water

$7,679.9

($80.2)

$7,599.7

$7,483.4

($30.9)

$7,452.5

Global Institutional & Specialty

5,962.0

(1.4)

5,960.6

5,979.4

(217.5)

5,761.9

Global Pest Elimination

1,219.2

(9.3)

1,209.9

1,140.1

Global Life Sciences

706.1

670.5

Subtotal at fixed currency

15,567.2

(90.9)

15,476.3

15,273.4

(248.4)

15,025.0

Effect of foreign currency translation

514.0

468.0

Consolidated reported GAAP net sales

$16,081.2

$15,741.4

Operating Income

2025

2024

(millions)

 

Fixed
Currency

Impact of Acquisitions and Divestitures

Organic

Fixed
Currency

Impact of Acquisitions and Divestitures

Organic

Global Water

$1,263.9

($10.1)

$1,253.8

$1,207.2

$0.2

$1,207.4

Global Institutional & Specialty

1,357.8

0.5

1,358.3

1,202.2

(52.9)

1,149.3

Global Pest Elimination

237.1

(0.5)

236.6

209.7

Global Life Sciences

120.7

91.8

Corporate

(195.2)

(195.5)

Non-GAAP adjusted fixed currency operating income

2,784.3

(10.1)

2,774.2

2,515.4

(52.7)

2,462.7

Special (gains) and charges

158.0

(183.4)

Subtotal at fixed currency

2,626.3

2,698.8

Effect of foreign currency translation

111.3

103.6

Consolidated reported GAAP operating income

$2,737.6

$2,802.4

Table of Contents

Global Water




		2025			2024			2023
Sales at fixed currency (millions)			$7,679.9			$7,483.4			$7,284.1
Sales at public currency (millions)			7,982.4			7,775.9			7,625.5

Organic sales change			2	%		*
Acquisitions and divestitures			1	%		*
Fixed currency sales change			3	%		3	%
Foreign currency translation			-	%		-	%
Public currency sales change			3	%		2	%

Operating income at fixed currency (millions)			$1,263.9			$1,207.2			$1,042.1
Operating income at public currency (millions)			1,332.9			1,274.2			1,115.4

Fixed currency operating income change			5	%		16	%
Fixed currency operating income margin			16.5	%		16.1	%		14.3	%
Organic operating income change			4	%		*
Organic operating income margin			16.5	%		16.2	%		*
Public currency operating income change			5	%		14	%

* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales increased 3% in 2025. Organic sales for Global Water increased 2% in 2025 driven by growth in Food & Beverage and Light & Heavy. Organic sales increased in 2024 driven by strong new business wins and value pricing which overcame uneven end-market trends.

At an operating segment level, Light & Heavy organic sales increased 2% in 2025 reflecting double-digit growth in global high-tech, improved growth in downstream and solid manufacturing sales growth, which more than offset soft end-market demand in basic industries. Global high-tech reported strong double-digit sales growth driven by data centers and microelectronics. Downstream reported sales growth in North America was partially offset by softer sales in other international regions. Manufacturing reported solid growth driven by food & beverage. Basic Industries sales declined as new business wins were more than offset by continued soft end-market demand. Light & Heavy organic sales increased in 2024 reflecting strong growth in downstream and manufacturing. Downstream reported strong sales growth in 2024, driven by strong growth in refining and water management. Manufacturing reported strong sales growth in 2024 driven by strong performance across institutional, food & beverage and high-tech. Basic industries reported sales growth in 2024 driven by new business wins that overcame softer market trends. Food & Beverage organic sales increased 4% in 2025 as value pricing and new business wins overcame continued soft industry demand. Organic sales increased in 2024 as good new business wins more than offset continued soft industry demand. Paper organic sales declined 3% in 2025 as continued new business wins were more than offset by ongoing soft customer production rates. Organic sales were flat in 2024 as strong new business wins were offset by soft customer production rates.

Operating Income

Organic operating income and organic operating income margin for Global Water increased in both 2025 and 2024 when compared to prior periods.

Organic operating income margin increased 0.3 percentage points during 2025 compared to 2024, as the 1.1 percentage point positive impact of value pricing was partially offset by the 0.9 percentage point negative impact of investments in the business. Organic operating income margin increased in 2024 compared to 2023, as the positive impacts of lower delivered product costs, strong value pricing, and higher volumes were partially offset by the negative impacts of investments in business.

Table of Contents

Global Institutional & Specialty




		2025			2024			2023
Sales at fixed currency (millions)			$5,962.0			$5,979.4			$5,779.4
Sales at public currency (millions)			6,104.6			6,103.4			5,910.8

Organic sales change			3	%		*
Acquisitions and divestitures			(4)	%		*
Fixed currency sales change			-	%		3	%
Foreign currency translation			-	%		-	%
Public currency sales change			-	%		3	%

Operating income at fixed currency (millions)			$1,357.8			$1,202.2			$856.5
Operating income at public currency (millions)

ECOLAB INC. 10-K